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GENERAL INTRODUCTION 
Dissertation Organization 
My dissertation is centered around the mechanism by which basic fibroblast 
growth factor regulates the three highly similar mrp/plfger\e promoters. I begin 
with a basic introduction on what is known about transcriptional regulation of gene 
expression. I then introduce the MRP/PLF family of proteins and what is known 
about them, followed by a description of basic fibroblast growth factor (bPGF) and 
the signal transduction components that are known to transduce its signal to 
regulate gene expression. One journal paper and another study follow, the first 
paper (second chapter) contains results obtained by Dr. Manzoor Mohideen who 
discovered that one of the known mrp/plf gene promoters is stimulated by bFGF. 
He also identified an element (the FRE) that contains a unique base pair in the 
mrp3 promoter which binds to specific proteins in 3T3 cell nuclear extracts and is 
protected in DNA footprinting experiments (Figs. 2, 3, and 5A). My results Include a 
comparison of all three of the known mrp/plf gene promoters' response to serum, 
platelet derived growth factor as well as bFGF. I demonstrate that the FRE is a 
functional transcription element that is regulated by bFGF. I further demonstrate 
that the protein(s) binding to the FRE in mobility shift assays are not AP1 
transcription factors, are partially competed for using the respective sequences in 
the other known mijj/plf gene promoters and these binding proteins are also found 
in day 11 placentae and fetal nuclear extracts. In the third chapter, 1 characterize 
the protein(s) that are able to bind to the FRE and the respective sequences in the 
other mrp/plf gene promoters and further elucidate the mechanism, suggesting a 
2 
model for the stimulation of the mrp3 promoter by bFGF. I then give a general 
conclusion of the results I've obtained, discuss what these results mean and 
suggest possible experiments to further characterize the protein(s) which bind to the 
FRE and to further dissect the mechanism of transcriptional regulation of the mrp/plf 
gene promoters by bFGF. The appendix contains studies to purify and further 
characterize the proteins binding to the FRE, P42, and P149, followed by a 
reference section for the general introduction and general conclusions. 
General Transcriptional Requirements and Its Control 
The control of transcriptional regulation resulting in gene expression involves 
the interaction of protein factors with specific DNA sequence elements. A common 
set of protein factors required for the expression of all eukaryotic genes is termed 
the basal transcriptional machinery. The basal transcriptional machinery includes 
RNA polymerase II and the general transcription factors (GTFs). The GTFs include 
TFIID which is a large multi-protein complex made up of the TATA-binding protein 
(TBP) which binds the TATA element found on many promoters and the TBP-
associated factors or TAFs. The basal transcriptional machinery recognizes the 
core gene promoter (the TATA element and the initiation sequence (Inr)) and 
initiates transcription. 
Several other proteins are involved in activating or repressing the 
transcription of genes. These proteins also bind to sequence-specific sites on the 
DNA. There are several positive and negative regulatory cis elements uniquely 
arranged as to the number, type and spatial arrangement in gene promoters. These 
elements are binding sites for sequence-specific transcription factors that activate 
or repress transcription of the gene. Another type of positive regulatory element 
found in genes is the enhancer. Enhancer elements can be found at great 
distances both upstream and downstream of the transcriptional start site and can Ije 
orjented in either direction relative to the direction of Uanscription. 
Transcription factors can be divided into families based on their structural 
motifs for recognition of specific DNA sequences. These structural motifs include 
homeodomains, zinc finger proteins, steroid receptors, leucine zipper proteins and 
h l^ix-loop-helix proteins. In general, transcription factors contain multiple domains, 
each domain performing different functions. These domains include a DNA-binding 
domain which is responsible for binding to a sequence-specific site on the DNA, one 
or more activation domains and dimerization domains. The different types of 
activation domains that have been identified in various DNA-binding proteins 
include: acidic, alanine-rich, glutamine-rich and proline-rich domains. These 
activation domains function to allow protein-protein interactions between the DNA-
bound regulatory transcription factors and either co-factors or members of the basal 
transcriptional machinery. Co-factors are proteins that do not bind to specific DNA 
sequences but instead form a bridge between DNA-bound proteins and the proteins 
involved with the basal transcnptional machinery (reviewed in 1,2). Dimerization 
domains allow transcription factors within families to form homo or heterodimers on 
sequence-specific sites on the promoter. This allows for a greater diversity in 
regulating gene expression owing to the fact that heterodimers can be either 
activators or repressors as can homodimers, can aquire difFerent DNA-binding site 
specifidties from homodimers and can t>e targeted to different sites than 
homodimers. Heterodimerization can also change the regulatory properties of a 
molecule bound at a fixed DNA site (reviewed in 3, 4, 5) 
Although many people think of transcription as being activated by certain 
stimuli, of equal importance is the repression of transcription. Various mechanisms 
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of transcriptional repression have recently t)een observed. Repressors 
(transcription factors that repress transcription) can compete for activator proteins 
binding to their sequence specific DNA elements. Quenching is also a means by 
which repressors can prevent activators from regulating gene expression. This 
occurs by a repressor dimerizing with an activator protein, the latter which is bound 
to the DNA. The repressor protein then quenches the activator protein's activation 
domain, essentially preventing the activator from functioning even if it is bound to 
the DNA A more active repression occurs when the repressor protein binds a co-
factor that an activator needs to bind to in order to convey its activation message, 
essentially the repressor interrupts the activator's signal to the basal transcriptional 
machinery (reviewed in 2,6,7). 
Mitogen Regulated Protein/Proliferin 
Mitogen Regulated Proteins (MRPs) were first identified and described by 
Nilsen-Hamilton et al. (8) as a family of glycoproteins that are secreted by Swiss 
3T3 cells upon stimulation by mitogens. A few years later, Linzer and Nathans (9, 
10) and Linzer et al. (11) identified two highly identical cDNA clones derived from 
growth related mRNAs, one from BALB/c3T3 cells and the other from placentae of 
BALB/c mice. The proteins encoded by these mRNA molecules are called proliferin 
(PLF1 and PLF2, respectively). Nucleotide sequence analysis between an mrp 
cDNA clone (12) and the two p^cDNAs demonstrated an exact match of 226 base 
pairs between corresponding sequences, immunological studies using anti-sera to 
MRPs demonstrated that MRPs and the PLFs in their glycoslylated and 
nonglycosylated forms are antigenically the same (12,13). This evidence along with 
a similar response of p/f mRNA in Swiss 3T3 cells stimulated with FGF (13), as had 
been previously shown in BALB/c3T3 cells in response to serum and platelet 
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derived growth factor (PDGF) (9, 10), demonstrated that MRPs and PLFs are very 
similar proteins encoded by multiple genes. Therefore, throughout this thesis, in 
general, this family of proteins and their genes will be referred to as MRP/PLFs or 
mrp/plfs, respectively, except when the specific gene is identified it will be referred 
to by its specific name. 
MRP/PLFs are secreted glycoproteins with relative molecular weights of 
34 kDa. Based on amino acid sequence, MRP/PLFs are 37% identical to bovine 
prolactin, 22% identical to bovine growth hormone, 32% identical to murine 
prolactin, and are therefore classified as members of the prolactin-growth hormone 
gene superfamily (10). Mrp/ptfs are expressed in the mouse placenta, specifically in 
the trophoblastic giant cells during days 7 through 13 of gestation, the time of rapid 
placental growth (10, 14-17). MRP/PLFs are secreted into the maternal blood 
stream reaching a peak concentration on day 10 of gestation (14). Immuno-
histochemical and RT-PCR studies have demonstrated that MRP/PLFs are also 
found in the fetal heart and vertebral column (18) and in the adult healing wound 
and hair follicles (19). The observation of the endogenous sites of MRP/PLFs 
expression and the secretion of MRP/PLFs into the maternal blood stream suggests 
a physiological role for MRP/PLFs during mouse development. 
MRP/PLFs have been shown to bind to two different cell surface receptors. 
Molecules of MRP/PLFs which contain a mannose-€-phosphate group bind to the 
cation-independent mannose-6-phosphate receptor, which is also the IGF-II 
receptor, in membrane preparations firom d11 maternal and fetal liver as well as the 
placenta (20). PLF1 is an angiogenic factor in rat cornea studies and stimulates 
endothelial cell migration (21). Volpert et al. (22) have recently demonstrated that 
this function of PLF1 occurs via the IGF-ll/mannose-6-phosphate receptor. 
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Because PLF1 activates phospholipase C through the mannose-6-phosphate 
receptor (23), this may be the pathway through which PLF1 functions as an 
angiogenic factor. MRP/PLFs also bind to a specific-high affinity receptor identified 
in murine mammary and uterine membrane preparations from d11 gestation (24). 
Addition of MRP/PLFs to these uterine ceil cultures causes an increase in the rate 
of DNA synthesis (ibid.). This data suggests that MRP/PLFs are secreted placental 
hormones that may function as murine uterine growth factors and stimulate uterine 
growth during gestation. Expression of plf1 also inhibits muscle cell differentiation 
(25) by suppressing the level and/or the activity of a trans-acting factor (CBF) that 
modulates multiple muscle-specific genes (26). 
Several mouse cell lines produce MRP/PLFs including Swiss 3T3 cells (8), 
BALB/c 3T3 cells (9), BNL (12), Krebs ascites carcinoma cells (10) and 10T1/2 cells 
(25). Several mitogens stimulate the synthesis of MRP/PLFs by 3T3 cells. Basic 
fibroblast growth factor (bFGF), epidermal derived growth factor (EGF), 
transforming growth factor-a (TGF-a) (8,15, 16), serum (8,12) and phorbol esters 
(27) stimulate the secretion of MRP/PLFs by Swiss 3T3 cells. BALB/c 3T3 cells 
increase their secretion of MRP/PLFs in response to serum (10,12) and platelet 
derived growth factor (PDGF;10). Of these mitogens, bFGF appears to have the 
greatest stimulatory effect in 3T3 cells (Nilsen-Hamilton, unpublished observation). 
There are multiple genes in the mouse genome that encode MRP/PLFs. It 
has been reported that there are four (28), five (29) or six (30) mrfj/plf genes in the 
mouse genome. One full length genomic clone has been isolated from Swiss CD-I 
mouse embryo DNA and is named mrp3 (28). The cloned mrp3 gene includes all 
of its introns and exons as well as 2000 bp of its 5' upstream sequence (ibid.). Five 
cDNAs for MRP/PLFs have been cloned. Plf1 cDNA was derived from the mRNA of 
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serum stimulated BALB/c3T3 cells (9, 10) and was later found to be in Ehrlich 
carcinoma cells along with an alternatively spliced form lacking exon three (31). 
Plf2 cDNA was derived from the mRNA of late gestational BALB/c mouse placentae 
(11). A partial mrp3 cDNA was cloned from BNL cells (12), and more recently mrp4 
cONA was cloned from the mRNA of d13 mouse placenta (32). The predicted 
amino acid sequences of PLF1, PLF2 and MRP3 mRNAs encode precursor proteins 
of 224 amino acids while MRP4 mRNA encodes a precursor protein of 222 amino 
acids. Ail contain an initial 29 residues resembling the signal sequences of pre-
hormones (10, 32). Therefore, the mature peptides for PLF1, PLF2 and MRP3 are 
predicted to k>e comprised of 195 amino acids and 193 amino acids for MRP4. 
Three consensus N-glycosylation sites (Asn-X-Ser), appear within PLF1, PLF2 and 
MRP3 while only one appears in MRP4 (10, 32). The mature 195 amino acid 
peptide sequences between PLF1, PLF2 and MRP3 are highly similar; PLF1 and 
PLF2 differ in three amino acids, PLF1 and MRP3 differ in two amino acids and 
PLF2 and MRP3 differ in only one amino acid (29). MRP4 differs between PLF1, 
PLF2 and MRP3 to a greater extent than the differences in amino acids found 
between PLF1, PLF2 and MRP3. Excluding the two amino acids absent in MRP4 
compared with the others in the mature peptide, MRP4 differs from PLF1 by 17 
amino adds, PLF2 by 13 and MRP3 by 12 (32). 
Three promoters for mrp/p/f genes have been cloned. As described 
previously, 2000 bp of the mrp3 promoter has been cloned and 1100 bp has been 
sequenced (29). Partial genomic sequences containing the first exon, 300 bp of the 
first intron and 1100 bp of upstream sequence for two other genes have also been 
cloned (30). These two clones designated ptf42 and p/f149, were obtained from a 
BALB/c 3T3 mouse genomic library. Ptf42 and ptf149 have been sequenced up to 
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-527 (30). Comparison of the three genes t)etween -527 to +99 (the end of the first 
exon) shows that mrp3 is 98.4% identical to pff42 and 97.4% identical to plf149 (29) 
while plf42 and plf149 are 97% identical (30). Comparison between the available 
genomic coding sequence of ptf42 and plf149 and the derived amino acid sequence 
from ptf1 and plf2 cDNAs reveal that either plf42 or plf149 may t)e the promoter 
sequences for the plf1 gene, but not the plf2 gene (30), which is yet to be cloned. 
Basal transcriptional elements as well as several regulatory elements have 
been identified in the rnqj/pff promoters. The TATA box is located between -23 and 
-29 upstream of the transcriptional start site and no CAAT box is evident (29, 30). 
An AP1 consensus binding site has been identified at -231 to -225 (29) and a 
second putative AP1 binding site at -208 to -202 was found based on a sequence 
search using the Tess computer program (33). Gene expression studies of the 
plfA2 promoter in response to serum (30) and phorbol esters (34) have identified the 
serum response/TPA response element to include the AP1 site at -231 to -224 
along with three imperfect repeats at -223 to -204, which are similar to the simian 
virus 40 SphI element. The major dimer of API proteins binding to the serum 
responsive AP1 site has been demonstrated to t)e the Fral, JunB heterodimer (35). 
The protein(s) which bind to the SphI-like elements have not been identified, 
however they do not appear to be the TEF which binds the SphI sites in the SV40 
promoter (35). 
Another transcriptional element that has been identified and studied in the 
plf42 promoter is the composite glucocorticoid response element (cGRE). The 
cGRE lies between -254 and -230 which overiaps the upstream AP1 element 
Mordacq & Linzer (34). This overiap accounts for the positive and negative 
regulatory effects of this piece of the promoter in response to glucocorticoids. 
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When cJun-cJun homodimers are present on this AP1 site, the cGRE/negative 
element stimulates gene expression of a minimal promoter in response to 
glucocorticoids, whereas the presence of cJun-cFos heterdimers causes a negative 
response following treatment with glucocorticoids (36). More recently, Hoeppner et 
al. (37) have identified another protein, different than the glucocorticoid receptor 
that binds to the cGRE and acts as a position dependent, glucocorticoid-
independent negative regulator of p/f42 gene expression. Thus, this site has now 
t)een termed the cGRE/negative element (37). 
GATA factors also effect mrp/plfs gene expression (38, 39). Placental cell 
cultures from transgenic and knockout mice for a mutant form of GATA2 and GATA3 
transcription factors demonstrated a decreased content of mrp/pffmRNAs and 
proteins (39). The rnqj/plf gene promoters contain several potential GATA 
recognition motifs including GATAG at -281 to -286, GATTT at -239 to -235, and 
GATAA at -161 to -157 (38) which may effect mrp/plf gene expression in vivo. 
Fibroblast Growth Factor 
Basic fibroblast growth factor (bFGF), also called FGF2 is a member of a 
family of fibroblast growth factors. The protein products of this family are encoded 
by 10 different mammalian genes and have been termed FGF1-FGF10. Basic FGF 
lacks a classical signal sequence for secretion and appears in the nucleus raising 
the question of its mode of exit from cells. Different species of bFGF are produced 
in cells having molecular weights ranging from 18.5 to 24 kDa. The differences in 
molecular weight are due to different translation products from the same mRNA that 
can initiate at three different CUG codons upstream of an AUG start codon. This 
results in proteins that are identical to the 18.5 kDa form but with additional N-
terminal amino acid sequences (reviewed in 40). Further diversity of the bFGFs 
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result from post-translational modifications which include glycosylation, methylation 
of nuclear forms, phosphorylation, ribosylation and nucleotidylation (reviewed in 
41). The different species of bFGF and their modifications may account in part for 
the various physiological effects of bFGF on many biological systems. 
Basic FGF is a ubiquitous growth factor that has t>een found in all cell types, 
tissues, organs and tumors in both the developing and adult organism. This growth 
factor exhibits a wide variety of biological functions including cell proliferation, cell 
differentiation, modulation of cell motility and extension of neurite outgrowth. 
These functions of bFGF demonstrate its importance in the physiological processes 
which are known to involve this growth factor. These physiological processes 
include bFGF's role in embryo and fetal development as well as its role in 
neovascularization and its responses to wounding (reviewed in 40, 41, 42). 
Basic FGF binds to two different types of receptors, the FGF receptors and 
the heparin-sulfate proteoglycans, forming an FGF receptor signal transduction 
complex at the cell surface. The FGF receptors (FGFRs) belong to the larger 
receptor tyrosine kinase family of signaling molecules. The FGFRs themselves are 
a family of multiple products from four different FGFR genes. All FGFRs exhibit 
three main structural motifs; an extracellular domain, transmembrane domain and 
an intracellular domain. The extracellular domain consists of 2-3 Immunoglobulin-
like loops named Ig-loop I, II, or III in the order of their Increasing proximity to the 
plasma membrane. Loop II is invariant among the different FGFR forms and 
composes the primary heparan sulfate and FGF binding site. The intracellular, 
cytoplasmic domain consists of two tyrosine kinase domains divided by a kinase 
Insert, and a C-terminal tail. A high degree of diversity is obtained from some of 
the individual FGFR genes through combinatorial alternative splicing and by 
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postranslational modifications of the protein product. These splice variants possess 
different binding affinities and ligand-binding specificities for the different FGFs 
(reviewed in 40, 42-44). 
While FGFs bind to FGFRs with high affinity FGFs can also bind to heparan 
sulfate proteoglycans with low affinity. The binding of FGF to various heparan 
sulfate proteoglycans on the cell surface has been proposed to reflect a role for 
these proteoglycans in maintaining the stability of FGFs by limiting their proteolytic 
cleavage, in increasing the retention of FGF by serving as a reservoir for long term 
storage sites, and in sequestering the FGFs either away from or in proximity to the 
signal-generating FGFR complexes (reviewed in 40, 42). In the presence of 
proteoglycans, FGF has an increased affinity for the FGFR. This may serve to 
stabilize FGF-FGFR interactions which would increase their observed affinity. 
Alternatively proteoglycans could facilitate ligand-receptor binding and receptor 
activation through conformational changes that could be induced in either or both 
partners (reviewed in 41). 
Upon binding of the ligand, FGF receptors dimerize to activate the receptor's 
tyrosine kinase to autophosphorylate on tyrosine residues. Substrates for the 
FGFRs are then activated eliciting the response to FGF down a signal transduction 
pathway. Currently, the known substrates for FGFRs include PLCy, the regulatory 
subunit of phosphatidyl inositol (PI)-3 kinase-p85 (reviewed in 40, 42), and more 
recently FRS2 (45). PLCy is activated by phosphorylation and once activated it can 
hydrolyze phosphatidyl inositol into inositol 1,4,5-triphosphate (IPS) which can 
increase the release of intracellular Ca*  ^and diacylglycerol (DAG) which can then 
activate protein kinase C (PKC). Activated PI-3 kinase can phosphorylate 
phosphatidyl-inositol produdng the phospholipid, phosphatidyl-inositol-3-
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phosphate. FRS2 is a novel lipid-anchored docking protein that is activated upon 
FGF1 stimulation and forms a complex with GRB2/S0S linking the FGFR activation 
to the RAS/MAPK signaling pathway (45). 
Several genes are regulated by bFGF and the mechanism of this regulation 
is just beginning to be identified. It appears that the mechanism is different 
depending on the promoter and the specific cell type for certain promoters. 
The rat osteocalcin gene promoter is transcriptionally activated by FGF2 in 
MC3T3-E1 osteoblast cells and this activation has been mapped to the segment 
-144 to -138 (GCAGTCA), the OCFRE (46, 47). By itself, this element in the rat 
OC promoter is not induced by bFGF, but this element is necessary and specific for 
the synergistic effect between FGF2 and forskorlin which activates cAMP (47). 
Three tandem repeats of the OCFRE upstream of the minimal OC promoter (-92 to 
+32) was not stimulated by FGF2. However, two or more copies of the OC promoter 
Fragment -154 to -113 allowing 42 bp between each OCFRE, upstream of the 
minimal OC promoter or the RSV minimal promoter is capable of conferring FGF2 
responsiveness, indicating a need for a bipartite element for the FGF2 
transcriptional activation of the rat OC promoter (46). The protein(s) in FGF2 and 
FGF2/FSK stimulated nuclear extracts from MC3T3-E1 cells which bind the OCFRE 
in gel shift assays is sequence specific and members of the ATF, Fos, and Jun 
Amities are not immunologically detected in this inducible DNA binding activity (47). 
The transcriptional activation of the OCFRE is mitogen-specific as EGF, PDGF, 
TGFbeta and IGF-1 do not activate this element (46). Activation of OCFRE by 
FGF2 proceeds via an okadaic acid and vanadate sensitive phosphatase pathway 
(46). The FGF2 activation of the human interstitial collagenase promoter (MMP1) is 
not inhibited by okadaic acid and vanadate, demonstrating two pharmacologically 
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distinct signal cascades that activate transcription in MC3T3-E1 osteoblasts (46). 
The regulation of the human interstitial collagenase (MMP1) gene promoter 
by bFGF is cell type specific. FGF2 stimulates transcription of the human interstitial 
collagenase promoter in MC3T3-E1 osteoblast cells, human smooth muscle cells 
and NIH3T3 fibroblasts (48-50), but down regulates its expression in keratinocytes 
(51). Ttiis difference between cell type specific regulation of human collagenase 
gene expression is due in part to the differences in the specific FGFRs found on the 
cell's surface (61). The bFGF responsive element on the human collagenase 
promoter consists of both an API element (TGAGTCA) and an Ets element 
(AGGATG) located between -100 to -61 base pairs upstream of the transcriptional 
start site (48). FGF2 upregulates a DNA-binding activity that recognizes the MMP1 
AP1 site and contains immunoreactive Fra1 and c-Jun (48). However, the DNA-
binding activity of the Ets element is present in constitutive and FGF2- stimulated 
nuclear extracts, but is not recognized by prototypic Ets transcriptional activators 
(48). The FGF2 transcriptional activation of the human interstitial collagenase 
promoter is mediated via a Ras- and MKP2-regulated MAPK pathway, is 
independent of ERK1/ERK2 MAPK activity in MC3T3-E1 osteoblasts, and 
converges on the bipartite Ets-API element (48). 
The rat prolactin gene is regulated by bFGF in the GH4 rat pituitary cell line 
and the bFGF response converges on two Ets elements centered around -212 and 
-96. Basic FGF induction of rat PRL is dependent on MAP kinase but the activation 
of MAP kinase does not occur via the p2l''^  and Raf-1 kinase. Basic FGF 
response sites on the pri promoter overiap with a Ras response element and an 
insulin response element, but these pathways utilize distinct nuclear factors to 
transduce their signal. The specific proteins binding to the bFGF Ets sites have not 
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been identtfied (52). 
Another promoter that is regulated by bFGF and cAMP synergistically 
activating its gene expression is the proenkephalin gene promoter. Basic FGF 
activates proenkephalin transcription via a Ras-dependent pathway ultimately 
converging on a CRE-like DNA regulatory element (CRE-2), a CREB/ATF binding 
site which has been shown to mediate gene activation by cAMP and Ca  ^
depolarization dependent pathway (53, 54). The tyrosine hydroxylase gene 
promoter also contains a CRE/CaRE element that is required for its induction by 
bFGF (55). 
The syndecan-1 gene encoding an integral membrane heparin sulfate 
proteoglycan is also induced by FGF2 via an FGF-inducible response element 
(FiRE). This 170 bp element contains five DNA motifs that include the binding of 
two FGF-inducible Fos-Jun heterodimers, one inducible AP2-related protein, a 
constitutively expressed upstream stimulatory factor and a constitutive 46-kOa 
transcription factor. At least four of the five motifs are required for the full activation 
of the FiRE by bFGF. This FiRE in the syndecan-1 gene promoter is activated by 
only FGF family members and not by PDGF, EGF, IGF or serum (56). 
Another promoter that is activated by bFGF is the skeletal a-actin promoter 
in cardiac muscle. The FGF regulation of this promoter is mediated by an SRE1 
element (57). 
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A UNIQUE bFGF-RESPONSIVE TRANSCRIPTIONAL 
ELEMENT 
A paper to be submitted to the Journal of Biological Chemistry. 
Manzoor-Ali P.k. Mohideen/-  ^Alesia Hruska-Hageman/ and Marit Nilsen-
Hamilton^* 
Abstract 
The mitogen-regulated protein/proliferin {mrp/ptf) genes belong to the 
prolactin/growth hormone gene superfamily and encode at least four closely related 
proteins. Identified functions of these proteins include stimulation of uterine 
proliferation and endothelial angiogenesis. In 3T3 cells, basic fibroblast growth 
factor (bFGF) stimulates the production of mAp/p/^ mRNAs with a resulting increase 
in the protein products. Although the three cloned mqj/plf gene promoters {mrp3, 
ptf42, and plf149) are over 97% identical in sequence, only mrp3 is transcriptionally 
activated by bFGF. We have identified a sequence in the mrp3 promoter, which we 
have named the "bFGF-responsive element" (FRE), that specifically binds nuclear 
factors from 3T3 cells. Analysis of the bFGF-responsiveness of a series of 
truncated mrp3 promoter sequences combined with footprint analysis, pinpointed a 
region of the promoter that contains a large variation in sequence between the three 
promoters and one base in the sequence that is unique to the mrp3. The nuclear 
factors bound by the FRE are present in the placenta and the fetus in which the 
^Department of Biochemistry, Biophysics and Molecular Biology and the Molecular, 
Cellular, and Developmental Biology Program. Iowa State University. Ames, lA 
50011 
^Currently Research Fellow in Medicine, Cardiovascular Research Center, 
Massachusetts General Hospital, Charlestown, MA 02129 
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gene is expressed. By contrast, the maternal liver does not contain FRE-binding 
proteins. The FRE is transcriptionally active in a TK fusion promoter and responds 
to bFGF in this context. Our results show that the FRE is a bFGF-responsive 
transcriptional element. The core sequence of the FRE is also found in the 
promoters of genes encoding the interstitial collagenase type-1 and stromelysin-1, 
that are also regulated by bFGF as delayed early response genes. The FRE 
element may be the means by which the expression of mrp3 and other genes are 
regulated by bFGF. 
Introduction 
The mitogen-regulated proteins (MRP/PLFs; also called proliferin) are a 
group of 34 kDa secreted glycoproteins that are encoded by several closely related 
genes (1-3). Based on amino acid sequence homology, the MRP/PLFs are 
members of the prolactin-growth hormone gene family (4,5). They are expressed in 
vivo by the trophoblastic giant cells of the murine placenta during days 9-13 of 
gestation (1,6,7). A specific receptor for these proteins appears in the 
midgestational uterus, coordinated with the expression pattern in the murine 
placenta of the mrp/pff genes (8). PLF1 stimulates proliferation of mouse uterine 
cells in primary cultures (8). It is also an angiogenic factor (9). The mrp/plfs are 
expressed in response to various mitogens and growth factors by 3T3 cells and 
their derivative cell lines as well as being expressed constitutively by BN/L and 
Eriich ascites cells (2,3,7,10-14). Wrp/p^mRNA has also been detected in the 
polyploid giant cells of trophoblast outgrowths (15). These giant trophoblast cells 
form the outermost layer of fetal cells in the murine placenta and express the mrp/plf 
genes in vivo (6). 
Five mrp/plf cDl4As have been cloned (12,13,16,17, Fassett, Nilsen-Hamilton 
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and Hamilton, in preparation). The protein sequences are between 91% and 98% 
identical. The promoters from three mrp/plf genes have been cloned (13,16). 
Although these promoter sequences are over 97% identical between positions -676 
and +65, we show here that the mrp3 promoter is uniquely activated by basic 
fibroblast growth factor (bFGF; FGF-2) via an element located within the first 353 
bp. 
Basic FGF is found in all tissues, tumors and cultured cells that have been 
examined (18). Its wide distribution is paralleled by its many proposed functions 
which include roles in biological processes such as the induction of ventral 
mesoderm, neovascularization, wound healing, cell proliferation, and cell migration. 
Several human birth defects have been linked to mutations in FGF receptors (18a). 
Basic FGF and FGF receptors are present in the placenta in which the mrp/plf 
genes are expressed (19,20). The addition of bFGF to mouse trophoblasts in 
culture enhances trophoblast outgrowths (21). Despite the importance of this growth 
factor, very little is known about the transcriptional signals by which bFGF regulates 
gene expression. 
Mrp/plf begins to increase about 8-10 h after the addition of bFGF to 
3T3 cells and peaks at 12-16 h. Increased mRNA synthesis in response to 
bFGF or to serum requires protein synthesis (3,22). Thus, mrp/plf is one of a group 
of delayed eariy response genes that are turned on in response to growth factors. 
Because of the length of the mammalian G  ^ phase of the cell cycle relative to the 
time period required to activate gene expression, it has been speculated that the 
products of delayed eariy response genes, rather than products of the immediate 
response genes, are more likely to determine the cell's decision to arrest in G  ^ or to 
enter S phase (23). Other delayed eariy response genes such as those encoding 
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proteases like collagenase and stromelysin play significant roles in the regulation of 
cell movement during development and in metastasis. 
In this study we have investigated the mrp/plf genes to identify a specific 
element by which bFGF regulates gene expression. The 5' upstream region of the 
mrp/plf gene contains many recognizable transcription elements. Three of these 
elements have been shown to be active in this gene or in other gene constructs. In 
L cells, CHO cells, and HeLa cells, Fos and Jun can regulate transcription through 
the composite GRE (cGRE) and adjacent API site (24,25). One or more of the 
GATA sites in the mrp/jo/f promoters are necessary for expression of these genes in 
the placenta (26). Here, we identify a new element that regulates gene expression 
and that responds to bFGF. Although this functional element has not yet been 
described in other genes, the sequence can be found in the 5' flanking regions of 
the genes encoding the interstitial collagenase type 1 and stromelysin-1, that are 
also regulated by bFGF. 
Materials and Methods 
Materials. Anti-Fos and anti-Jun were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA). Bovine basic FGF (bFGF-b) isolated from 
bovine brain was a gift from D. Gospadorowicz (Chiron Corporation, San Francisco, 
CA). Recombinant human bFGF (bFGF-rh) was from USB Corp. (Cleveland, OH) 
or R&D Systems, Inc. (Minneapolis, MN). Recombinant human PDGF-AA was 
purchased from R&D Systems, Inc. The plf42CAT and plf149CAT plasmids were 
gifts from D.I.H. Linzer (Northwestern University, Chicago, IL), The p2pCAT 
plasmid was a gift from D.T. Denhardt (Rutgers University, Piscataway NJ). The 
ptISTKCAT was a gift from S. Tapscott (Fred Hutchinson Cancer Research Center, 
Seattle, WA). R. Padmanhaban (University of Kansas Medical School, Kansas 
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City, KS) provided pRSVneo (27). The sequence of the HNF1 recognition site 
found at position -70 to -50 of the mouse albumin gene promoter (28) was used to 
prepare the HNF1 sense and antisense oligonucleotides (Life Technologies, Grand 
island, NY). The nonspecific competitor, A33T33 oligonucleotide (5-
II I I I I I GGCAAAAAAAAAAACAAAAATAGTAA-3') along with its complementary 
strand was a gift from Shawn Ahmed and Eric Henderson (Iowa State University, 
Ames, lA). Purified double stranded API consensus oligonucleotide (5-
CGCTTGATGAGTCAGCCGGAA-3') and the pCAT Basic vector were purchased 
from Promega, Corp. (Madison, Wl); poly(dl-dC):poly(dl-dC) was from Pharmacia 
Biotech, Inc. (Piscataway, NJ). All other oligonucleotides were prepared by the 
DNA Sequencing and Synthesis Facility (Iowa State University, Ames, lA). T4 
polynucleotide kinase was from Pharmacia Biotech, Inc. or the Promega 
Corporation. Other enzymes were from Promega Corporation. 
Cell culture. Swiss 3T3 cells were grown in Dulbecco-Vogt's modified 
Eagle's medium (DMEM) containing pyruvate and with 10% bovine calf serum and 
10 U/ml each of penicillin and streptomycin (GIBCO/BRL, Grand Island, NY) The 
ceils were maintained in a humidified atmosphere containing 10% COjand 90% air 
at 37'*C. Stably transfected 3T3 cells were maintained in medium that also 
contained 350 Mg/ml G418 (GIBCO/BRL). The cells were free of mycoplasma 
contamination as determined by ^ H-thymidine incorporation with autoradiography 
and by analysis of Hoechst 33258-stained cells. 
For preparing stable transfectants, 3T3 cells were plated at a density of 2.5 x 
10  ^cells per 100 mm dish. Cells were cotransfected with the reporter plasmid in 
combination with pRSVneo at a molar ratio of 5:1 (reporter plasmid: pRSVneo) with 
the total DNA per dish being 20 |jg. Transfections were performed using the 
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calcium phosphate procedure as described by Kingston (29). Stably transfected 
cells were selected in the medium which included 350 pg/ml G418. Control cells, 
which were not cotransfected with pRSVneo, did not survive the G418 selection. 
After 4 to 6 weeks of selection the stably transfected cells were pooled and ft'ozen in 
liquid nitrogen. To assay the transfected cells for bFGF induction, the cells were 
plated at 2,500 cells per cm  ^in 60 mm diameter dishes in OMEM containing 10% 
bovine calf serum. Three to 4 days later, bFGF was added at 5 ng/ml (bFGF-b) or 
1 ng/ml (bFGF-rh) in a buffer containing 0.005% bovine serum albumin, 1.4 mM 
NaCI, 50 mM KCI, 7 |jM Na2HP04, 0.25 mM Tris-HCI (final concentrations). Control 
cells received only the buffer. Twenty four to 30 h later the cells were harvested 
and lysates were prepared. 
Ptasmid construction. To prepare the mrp3(2kb)/CATBasic plasmid, the 
sequence -2000- to +65-bp of mrp3/plf3 was removed from pCKT-17-2/p2p by a 
C/al and Pstt double digest and ligated to a pCATBasic vector which had been 
previously prepared by being cut with H/ndlll, blunt-ended with Klenow Fragment, 
ligated to C/al linkers and then cut with C/al and Psfl. The pCKT-17-2/p2p 
construct had been generated from the plasmid p2pCAT that carried the -2000-bp 
to +65-bp mrp3 sequence. Deletion mutants were generated from the 
mrp3(2kb)/CATBasic plasmid to create the following lengths of promoter all ending 
at+65-bp and beginning at positions: -1350, -1100, -799, -681, -609, -575, 
-427, -353, -81, and -46. These mutants were created by digesting with EcoRI 
(-1350 and -1100), Avail (-799), Hindlll (-681 and -609), Ec»RV (-575), SsmFI 
(-427), Apo\ (-353), Afl\l\ (-81), and 8s(/36l (-46) restriction enzymes. The -1100 
to +65-bp Fragments of plf42 and plf149 were obtained by digesting plf42CAT and 
plf149CAT plasmids with HincMl and Pstt. These Fragments were ligated to 
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H/ndlll/Psfl-cut pCATBasic vectors to generate plf42CATBasic and plf149CATBasic 
plasmids. The -799, -681, -609, -575, and -427 deletion mutants of the pff149 
promoter were obtained by digesting pff149CATBasic with /Avail (-799), Hindlll 
(-681 and -609), EcoRV (-575), and SsmFI (-427) restriction enzymes. The 
mrp3-plf149CATBasic chimeric promoter construct was generated as follows: 
1165-bp EcoRl/Pst I Fragment from plf149CATBasic was ligated to a 900-bp 
CfaUEcoRl Fragment from mrp3(-2000/-1100)/pBKSII and to a Clal/Pstl-cut pCAT 
Basic vector in a three-piece ligation reaction. The pFRE3TKCAT plasmid 
construct was prepared by ligating the double stranded oligonucleotide which 
included 3 tandem copies of the FRE (-167 to -187 of the m/p3 promoter) containing 
a 5' Hindlll overhang and a 3' Xbal site to the pt18TKCAT vector cut with Hindlll and 
Xbal. The plasmid pti 8TKCAT includes the -109-bp to +51 -bp sequence of the 
Herpes Simplex Virus thymidine kinase promoter upstream of the CAT gene. 
CArassay. Cells were lysed in 0.25 M Tris CI, pH 8.0 by three freeze-thaw 
cycles. Lysates were heated to 68°C for 5 min then quickly cooled on ice. The CAT 
assay was performed by the method of Seed and Sheen (30) using 
^^C-chloramphenicol and n-butyryl CoA. Protein concentrations were determined 
for each cell lysate using the Coomassie Plus Protein Reagent from Pierce 
(Rockford, IL). The values for CAT activity were normalized to the protein 
concentration determined for the same lysate. 
Oligonucleotides and probes. The double-stranded oligomer 
corresponding to the bFGF-responsive element (FRE) was constructed by 
annealing the following two oligonucleotides; 5'-CTATATCAGTGAATCTAAAA-3' 
and 5'-M I iAGATTCACTGATATAG-3'. This sequence corresponds to the 
sequence from -167 to -186 of the m/p3 promoter sequence. Double-stranded 
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oligomers corresponding to the equivalent regions of the plf42 and plf149 promoter 
sequences were constructed by annealing the P42 and P149 oligomers (Fig. 1) with 
their respective complimentary strands. Annealing was performed in STE (100 mM 
NaCI,1 mM EDTA, 10 mM Tris CI. pH 8.0). Mutant FREs, mIFRE and m2FRE 
(Fig. 1), were annealed to their respective complimentary strands. Except when 
mentioned otherwise, oligonucleotides were annealed before being labeled. 
Double-stranded oligonucleotides were phosphorylated using 74 polynucleotide 
kinase (Promega) in the presence of [y-®P]ATP (4500 Ci/mmol; ICN 
Pharmaceuticals, Inc., Costa Mesa, CA), 0.1 mM EDTA, 10 mM NaCI, 10 mM 
MgClz, 5 mM DTT, and 70 mMTris CI, pH7.6. Unincorporated radiolabel was 
removed using STE SELECT-D, G-25 spin columns (5 Prime-3 Prime, Inc. Boulder, 
CO). For some experiments, oligonucleotides were phosphorylated before being 
labeled. For these, the single-stranded oligonucleotides were first purified by 
resolving them by urea-polyacrylamide gel electrophoresis. Following extraction 
from the gel, and prior to annealing or lat)eling, the urea and salts were removed 
using the Sep-Pak C^s chromatography column (Waters Chromatography Division of 
Millipore Corporation, Milford, MA). Single-stranded purified oligomers were 
phosphorylated using T4 polynucleotide kinase (Pharmacia Biotech inc.) in the 
presence of [y-^P]ATP (3000 Ci/mmol; NEN Dupont), 10 mM MgCIs, 5 mM DTT, 
and 70 mM Tris CI, pH 7.6,. After annealing, unincorporated radiolabel and single-
stranded oligonucleotides were removed by gel electrophoresis. The probes were 
stored in STE buffer at -20®C. 
Preparation of nuclear extracts. Nuclei were isolated from tissues (31) or 
log-phase 3T3 cells (32). MRP/PLF production is most effectively stimulated by 
bFGF in growing cells and it is not produced by quiescent cells (3,7). To 
determine the conditions for extraction of nuclear proteins, the procedure of Abmayr 
and Workman (32) was followed using extraction solutions of increasing salt 
concentrations (0.8,1.0, 1.2, 1.4, and 1.6 M KCI). The extracts were tested for their 
ability to bind to the FRE by the electrophoretic mobility shift assay (EMSA). 
Nuclear extracts from bFGF-induced ceils prepared with all concentrations of KCI 
tested seemed to have similar concentrations of factor(s) capable of binding to the 
FRE. Therefore, for all data shown here, nuclear extracts were prepared with 
1.2 M KCI. 
DNA'binding Etectrophontic Gei Mobility Shift Assay (EMSA). Binding 
reactions (20 (j') contained 300 (jg/ml BSA, 1.5 mg/ml protein (nuclear extract), 
60 mM KCI, 1 mM EDTA, 2 mM MgClj., 0.1 mM PMSF, 0.3 mM DTT, 100 Mg/ml 
poly(dl-dC) •poly(dl-dC), 20% glycerol, 4 mM Tris-CI, 12 mM HEPES-NaOH, pH 7.9 
and 0.25-0.5 ng double-stranded DNA probe. Wherever indicated, the reaction 
mixes also included specific and nonspecific competitors as controls for specificity 
of the binding reaction. The reaction mixes were incubated at 30° C for 20 min. 
DNA-protein complexes were separated from free probe by electrophoresis on 4% 
polyacrylamide gel (80:1 acrylamiderbisacrylamide) in 2.7 mM EDTA, 380 mM 
glycine, 2.5% glycerol, 50 mM Tris CI, pH 8.5. Gels were run at 10 V/cm, dried 
under vacuum and either e^qsosed to a PhosphorScreen (Molecular Dynamics, 
Sunnyvale, CA) and analyzed on a Phosphorlmager or exposed to Kodak X-Omat 
AR film at room temperature. 
DAfA footprinting DNA Footprinting Probes used in the DNA footprinting 
assays were generated by end-labeling at the Bsu361 end of the Mboil/Bsu361 
restriction Fragment (-254 to -102) from mrp3(-353/+65)CATBasic with [y -32PJATP 
using T4 DNA polynucleotide kinase. During the preparation of the Fragments the 
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Bsu36l end was dephosphorylated and therefore the reverse strand was labeled. 
The DNAse I protection footprinting reactions using the described probes and 
nuclear extracts from bFGF-stimulated 3T3 cells were performed using the 
SureTrack Footprinting Kit (Pharmacia Biotech Inc.). Binding reactions were carried 
out as in the EMSA analysis before treatment with DNAse I. The DNAse treated 
binding reactions were denatured (98"C, 2 min) and run on a 6%, 19:1 
acrylamideibisacrylamide, 89 mM Tris t)ase, 89 mM Borate, 2 mM EDTA, 6 M urea 
sequencing gel. Maxam and Gilbert G+A sequencing reactions (SureTrack 
Footprinting Kit) were run alongside the footprints in order to determine the 
sequence of the protected regions. After electrophoresis, the gel was dried, and 
autoradiography was performed. 
Results 
A unique transcriptional element in the mrp3 gene promoter. We 
compared two of the m/p/p/f promoters, mrp3 and plf149, for their responsiveness 
to bFGF using a series of truncated versions of the upstream nontranscribed 
sequences of the mrp3 and plf149 genes. CAT expression vectors were used to 
stably transfect 3T3 cells and the activity of the promoters was measured in lysates 
of the transfected cells (Fig. 2). Only the mrp3 promoter responded to bFGF with 
increased activity. The average increase was 2-4-fold with all constructs containing 
promoter segments larger than 81-bp. 
We investigated the possibility that the lack of stimulation by bFGF of the 
plf149 promoter was because a sequence upstream of -1100 bp was required. A 
chimeric promoter was constructed by ftjsing the -2000 bp to -1100 bp Fragment of 
mrp3 to the -1100 bp to +65 bp Fragment of pff149. The presence of the additional 
900 bp sequence from mrp3 did not result in activation of the plf149 promoter by 
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bFGF. Thus, it was concluded that the bFGF-responsive region is located between 
-81 bp and -353 bp on the mrp3 promoter. 
Footprints on the bFGF-responsive promoter segment The segment of 
the promoter from -256 to -102 was used to locate, by footprint analysis, sites on 
the promoter with which nuclear proteins interact with this region that contains the 
FGF-responsive element. A large region of this segment of the mrp3 promoter from 
-231 bp through -124bp was covered by a footprint (Fig. 3). This protected region 
includes several identified transcriptional elements and a duster of sequence 
variations between -177bp and -173bp (underlined sequence in the shaded box in 
Figure 1). This cluster contains most of the differences in sequence between the 
three promoters in the -353 to -81 segment of the promoter and It also contains the 
only base (position -173) unique to the sequence of the mrp3 promoter. As a result 
of evidence presented in the remainder of this report, the sequence including and 
surrounding this cluster of variation is referred to as the "bFGF-responsive element" 
(FRE). 
Lack of involvement of the AP-1 response element in bFGF-responsive 
promoter activity. The cGRE and AP-1 elements in the plf42 promoter have been 
identified as potentially involved in the serum response activity of that promoter 
(24,33). FOB is induced in 3T3 cells in response to stimulation by bFGF (34). The 
three promoters do not differ in the AP-1 sequence directly adjacent to the cGRE. 
However, we did note a potential AP-1 site with one variation from the consensus 
sequence that is located within the region of the sph repeats (labeled as API* in 
Fig. 1). Within this sequence there is one base change between mrpS and plf149. 
We therefore tested the ability of bFGF to stimulate expression from the plf42 
promoter and found that there was no stimulation (Fig. 2). API activity is increased 
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in response to serum and phorbol esters, the latter being mediated through protein 
kinase C (PKC). Downregulation of PKC by TPA also did not alter the ability of 
bFGF to stimulate the mrp3(-353) promoter (data not shown). Taken together, 
these data indicate that the AP1 recognition sites are not responsible for the bFGF-
responsiveness of the m/p3 promoter. 
The mrp3 promoter responds specifically to bFGF and not to serum or 
PDGF. in previous studies, Linzer and colleagues demonstrated that long-term 
exposure of mouse L cells to serum resulted in increased ptf42 promoter activity 
(13, 22) and that AP1 was responsible for this response to serum (25). The 
production of MRP/PLF by 3T3 cells is also suppressed when cells become 
quiescent or when the serum concentration is decreased (3,4) We tested the 
ability of serum to increase mrp/pff promoter expression under our assay conditions 
in which the time of exposure to serum is 24 h or less. In these experiments we 
also determined the effects on the activity of mrp3, plf42, and plf149 of serum and 
PDGF (Fig. 4). PDGF was also tested because it is the major growth factor in 
serum. Only bFGF stimulated the mrp3(-1100) promoter. The plf149(-1100) and 
plf42(-1100) constructs did not respond to any of the growth stimuli and also did not 
respond to a combination of PDGF and IGF-1 (data not shown). 
Interaction of soluble nuclear factor(s) with the PRE. To examine the 
interaction of the FRE with nuclear proteins, EMSAs were performed with an 
oligonucleotide containing the FRE sequence (Fig. 1) and nuclear extracts prepared 
from 3T3 cells that had been stimulated with bFGF. One retarded band was 
observed. Excess unlabeled FRE oligonucleotide competed successfully for 
binding to the nuclear factor(s) (Fig. 5A). There was no reproducible difference in 
the proportion of probe that was shifted by extracts from control cells, which had not 
27 
been previously treated with bFGF, and extracts from bFGF-stimulated cells (data 
not shown). 
The specificity of the FRE-binding protein(s) (FREBP) for the FRE sequence 
was tested by determining whether the closely related sequences in p/f42 and 
plf149 would compete for binding to the FRE oligonucleotide. Both 
oligonucleotides, P42 and P149 competed with the FRE but higher concentrations 
were required for this competition than if the FRE were the competitor. When the 
ratio of competitor to probe was 10 to 1, the FRE reduced the binding by 74% and 
the P42 and PI49 oligonucleotides reduced the amount of shifted band by 20% and 
42% respectively. Two mutant oligonucleotides ml FRE and m2FRE (Fig. 1) 
reduced binding by 35% and 48% respectively. The single base change in m1 FRE 
corresponds with the unique base in the mrp3 FRE sequence. The base changed 
in m2FRE corresponds to the second difference between nirp3 and plf149 in the 
region of the FRE. 
In experiments to establish which segment of the FRE oligonucleotide was 
bound by proteins in the 3T3 cell nuclear extracts, we found that an oligomer (-179 
to -162bp) containing the 3' 2/3 of the segment of the FRE oligonucleotide 
competed with the FRE oligonucleotide for binding. However, an oligomer (-191 to 
-174) containing the 5' 2/3 of the segment of the FRE oligonucleotide did not 
compete (Fig. 58). From these experiments we conclude that the FREBP 
recognize the FRE specifically and with higher affinity than they recognize the 
equivalent plf149 or plf42 sequences in oligonucleotides PI49 and P42. Also, 
stable complexes are only formed on the 3' 2/3 of the FRE sequence. 
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Fos and Jun are not part of the FRE-binding complex. Expression of 
plf42 is stimulated by phortx)! esters in mouse L cells (33) and MRP/PLF protein 
and mRNA levels also increase in response to phorbol myristate acetate in 3T3 
cells (11). Expression from plf42 in response to serum in L cells is mediated by 
AP1 (25). bFGF also increases cFos and cJun expression (34). So, it seemed 
likely that the bFGF-responsive element in the mrp3 promoter might involve one or 
both of these transcription factors. However, the FRE oligonucleotide does not 
contain an AP1 recognition element and the presence of AP1 sites in pff42 was not 
suffident for bFGF regulation of this promoter. Thus, if Fos or Jun were part of the 
complex with the FRE oligonucleotide, they would have to be associated by 
interaction with an FREBP. 
We tested whether Fos or Jun might be part of the complex that binds the 
FRE. First, an oligonucleotide containing the AP1 recognition sequence was used 
as a competitor for the FRE in EMSAs. The AP1 oligonucleotide did not compete 
for factors that bind the FRE, and there was no change in the mobility of the shifted 
complex in the presence of the AP1 oligonucleotide (Fig 5A and Fig. 6). We also 
examined the possibility that AP1 might be a component of the FRE-binding 
complex by using antibodies to Fos and Jun to supershift AP1-containing 
complexes. The mobility of the FRE complex was not altered by the inclusion of 
antl-Fos or anti-Jun antibodies in the reaction mix; nor was the amount of the 
complex diminished by these antibodies (Fig. 6). By comparison, the complex 
formed by proteins in nuclear extracts with an oligonucleotide containing the AP1 
element was supershifted by incubation with anti-Jun and anti-Fos antibodies (Fig. 
6). From these data we conclude that Fos and Jun are not part of the FREBP-FRE 
complex observed by EMSA. 
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Nuclear factors in the placenta and the fetus bind the FRE. Three of the 
cloned mrp/plf genes are expressed in the placenta and in the embryo during 
development (34a, Dudley, Fassett, Nilsen-Hamilton and Hamilton, submitted). 
Therefore, we tested extracts from embryonic tissues to determine whether they 
contained nuclear factors capable of binding the FRE oligonucleotide. Proteins in 
nuclear extracts from 11-day placentae and fetuses interacted with the FRE 
resulting in two shifted bands (Fig. 7). The slower-moving band traveled at the 
same rate as the complex formed with nuclear factors from growth factor-stimulated 
3T3 cells. However, the faster-moving band was more abundant in txsth tissue 
extracts. Frequently a smear of mobility-shifted oligonucleotide was found t^etween 
the faster- and slower-moving bands as seen for the placenta in Fig. 7. This 
suggests that the slower moving band might be unstable under the conditions of 
electrophoresis and collapse to the faster moving band upon the dissociation of one 
or more components while traveling through the gel. As for the complexes formed 
with 3T3 cell extracts, the API oligonucleotide did not compete for the FREBP, and 
the shifted band containing the FRE oligonucleotide was not affected by incubation 
with anti-Jun or anti-Fos antibodies. 
Nuclear extracts of the maternal liver produced no mobility shift of the FRE 
probe although these liver nuclear extracts were shown to contain active 
transcription factors by their ability to shift the mobility of an oligonucleotide 
containing the HNF1 recognition element (Fig. 7). 
The FRE drives FGF-responsive expression of a heterologous 
promoter. The ability of the FRE to direct transcription was tested by making 
constructs in which one, two, and three copies of the FRE were appended upstream 
of the basal thymidine kinase (TK) promoter of the Herpes Simplex Virus. All three 
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of the resulting constructs drove expression of the linked CAT reporter gene in 
stably transfected cells at a rate of 10 to more than 200-times that of the basal TK 
promoter alone. Expression of the constructs containing one copy of the FRE was 
not regulated by bFGF. However, expression of the construct containing three 
copies of the FRE was regulated by bFGF (Fig. 8). In twelve of sixteen experiments 
in which each condition (with and without bFGF) was tested in triplicate, the extent 
of stimulation of the FRE3TKCAT by bFGF ranged firom 1.3 to 5.4-fold over the 
control. No stimulation was observed in the other four experiments. The average 
stimulation by bFGF from the 12 experiments was 2.5-fold (P<0.005). 
Discussion 
The mrp/plf genes are expressed in various adult and fetal tissues in tissue-
specific patterns (Fassett, Nilsen-Hamilton, and Hamilton, in preparation). The 
ability of the mrp3 gene to uniquely respond to bFGF may be partly responsible for 
the observed variation in tissue expression within this gene family. Our analysis 
identified the sequence tjetween -81 and -353-bp as containing the bFGF-
responsive element. This region has many putative regulatory elements and a 
segment that is protected from DNAse I degradation by components in nuclear 
extracts of 3T3 cells. The region containing the FRE was further delineated by the 
fact that the ptf42 and mrpS promoters are identical between -353 and -181 and 
differ at only four positions between -181 and -81. There is only one position (-173) 
in this segment in which mrp3 uniquely differs from p/f149 and pff42: mrp3 has a T 
at -173 while both pff42 and pff149 have a C. In this same region, within a stretch 
of nine bases f|-om -173 to -181, there are four positions where variations occur 
betvween mrp3, plf42, and plf149. This is the largest cluster of variation among the 
three mrp/plf promoter sequences in the FGF-responsive region of-81 to -181. 
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The DNA footprints on the mrp3 promoter show that a region from -234 
through -121 is protected by nuclear proteins fi"om 3T3 cells. The only variation in 
sequence between the three mrp/p/f promoters in this region is the cluster of 
variation between -173-bp and -181-bp. This cluster of variation is included in the 
FRE sequence which we have shown here mediates bFGF regulation of gene 
expression. The FRE sequence differs from any other element so far described and 
the protein(s) that bind the FRE preferentially recognize this sequence over the 
related sequences in the plf149 and plf42 promoters. Specificity of binding of the 
FREBP is also indicated by the fact that single base-pair changes at positions -173 
and -181 decrease the ability of the oligonucleotide to compete for binding to the 
FREBPs. 
The FRE sequence was compared with the sequences of known 
transcriptional elements using the Matinspector search program (35). None was 
found to t>e the same as the FRE. The most closely related sequence is the 
consensus sequence for the transcriptional repressor, Gfi-1 (36). This consensus 
sequence [TAAATCAC(A/T)GCA] contains the AATC motif also found in the FRE. 
Gfi-1 is a transcriptional repressor in the context of the T-cell lymphoma cells in 
which it was discovered. 
The GATA transcription factors have Ijeen demonstrated to be important for 
the expression of the mrp/plf genes in the placenta (26). The 5' 2/3 of the FRE 
oligonucleotide contains a potential GATA binding site and the footprint covers this 
region. However, the 5' 2/3 of the FRE oligonucleotide does not compete for 
binding of FREBP, whereas the 3' 2/3 of the FRE oligonucleotide does compete. 
Other GATA sites on the promoters are located outside the FRE sequence 
and are all conserved amongst the three promoters. Thus, it is unlikely that the 
32 
regulation of mrp3 expression by bFGF is mediated by a GATA transcription factor. 
In L-cells, AP1 mediates increased plf42 promoter activity in response to 
long-term exposure to serum. A much smaller effect of serum was observed with 
the ptf149 promoter (13). Whereas in previous studies, L cells were incubated for 
48h with serum after transfection and before harvesting the cells, our studies have 
routinely examined a more acute response of the cells to growth factors and serum. 
Here we show that serum does not increase expression from any of the mrp/pff 
promoters within 24 h of Its addition. Downregulation of PKC by TPA also did not 
alter the ability of bFGF to stimulate the mrp3(-353) promoter. Thus, the increase 
in AP1 activity resulting from bFGF stimulation probably does not influence mrp3 
promoter activity. We also found no evidence for the existence of Fos or Jun in the 
complex that binds the FRE. Antibodies that recognize these transcription factors 
and caused a supershift of a complex containing an AP1 site did not alter the 
mobility of the FRE complex. The reported specificity of the antibodies used in this 
study are broad; the anti-Jun antibody recognizes c-Jun-, JunB-, and JunD-
encoded proteins and the anti-Fos antibody recognizes vertebrate c-Fos-, FosB-, 
Fra1-, and Fra2-encoded proteins. Thus, it is unlikely that the FRE-bound complex 
includes a member of one of these two families of transcription factors. 
That the FRE is an bFGF-responsive element is demonstrated in that bFGF 
stimulates expression from a CAT-reporter construct in which three copies of the 
FRE are present upstream of a basal TK promoter. The mechanism by which 
bFGF regulates the activity of this element was not revealed in this study. We 
found no reprodudble difference in the proportion of shifted oligonucleotide or in the 
footprints when nuclear extracts from FGF-stimulated cells were compared with 
nudear extracts from unstimulated control cells. Thus, regulation by bFGF of the 
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FRE is prot>abiy not mediated by changing the amount of FREBP associated with 
the FRE. The presence of FREBPs in the placenta and the fetus, but not in the 
maternal liver, suggests that the expression of these FREBPs is tissue-specific or is 
specific for proliferating tissues. 
Using the GCG database search program we examined the promoters of a 
number of genes including those that are regulated by bFGF. We found a 
sequence similar to the (-181 to -172) FRE sequence upstream of the coding 
sequences in several other genes regulated by bFGF including interstitial 
coliagenase type 1 and stromelysin (Table I). Interestingly, as Is mrp3, both these 
genes are delayed early response genes. They also both encode secreted 
proteins. Other protease genes that are regulated by bFGF ( cathepsin L, 
cathepsin B, tissue plasmirxsgen activator) also contain a sequence similar to the 
FRE. Other protease genes not known to be regulated by bFGF (human elastase, 
human metalloelastase, mouse trypsin, rat pancreatic trypsin, rat chymotrypsin B) 
did not contain the FRE sequence or a closely related sequence. 
In conclusion, we have identified a new FGF-responsive DNA transcriptional 
element, the FRE, which is found in the mrp3 gene of the mrp/plffamWy with closely-
related sequences in the two protease-encoding genes, interstitial coliagenase type 
I and stromelysin. The MRP/PLFs and the two proteases are believed to be 
involved in tissue growth and remodeling. The MRP/PLFs have the demonstrated 
functions of stimulating angiogenesis (9) and uterine cell proliferation (8) and 
inhibiting myoblast differentiation (37). Depending on the stage of development or 
specific tissue, these functions might be performed in vivo by different isoforms of 
the MRP/PLF proteins whose Individual gene expressions are regulated differently. 
This study provides insight into the mechanism(s) by which the expression of one 
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isoform of MRP/PLF can be regulated at the transcriptional level independently of 
the other mrp/plf genes by bFGF. The presence of the FRE sequence in the 
promoters of other genes that also encode proteins involved in tissue growth and 
remodeling suggest that the FRE may be the means by which several genes are 
regulated by bFGF. 
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Fig. 1. The mrp/ptf promoter sequences and the "mrpS unique sequence" 
(FRE). Comparison of the sequences of the mrp3, pff42. and plf149 promoters in 
the region between -353 and -81. The sequence for mrp3 is shown in full. 
Wherever variations occur between mrp3, plf42 and plf149 the bases are indicated 
in bold and the bases of plf42 and plf149 are indicated, respectively, above and 
below the mrp3 sequence. The sequence information used for this figure was 
obtained from Linzer and Mordacq (13) and Connor et al. (16). The sequence 
enclosed by dashed lines is the cGRE. Potential GATA sites and API sites are 
enclosed in boxes and marked appropriately. The shaded box encloses the 
sequence that was used as a basis for preparing oligonucleotides. The region with 
the highest density of variations within that sequence is underlined within the 
shaded sequence and in the equivalent oligonucleotide sequence in the box at the 
bottom. The bottom box contains sequences of the sense strands of the FRE, 
mutated FREs (ml FRE and m2FRE), P42 and P149 oligonucleotides. The mutated 
bases in the FREs and the bases in P42 and P149 that differ from the FRE are 
indicated by bold letters. 
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mrp3 
plfl49 
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mrpS 
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mrp3 
plfl49 
plf42 
mrp3 
plfl49 
-353 
TTAGAATATA TAAAATCCTG AAGGTAAAAA GGTCTATGGC 
313 T ~GATA 
ATAGCTATTT ATTTAAAGCA AGTAATT TCT ATC^GTCTTT 
c 
-273 ' 
ATGAGGAAGA CATAGTTGlte GCTACTCACA GTATGATTTG 
-233 AP1 
Sph 1 repeats am* 
' t 
rajrAGTCAb AGCATGAACA TGAGAjrCAATjcACATACATA 
-GATA-
TCAA TCraAAAAAT AAGATAAACC 
-193 
GAACTGAjCIl 
i—GATA-' 
-153 G 
ATGAACTTAG AACTATATTA GTGTTCATGG TATCTAGGCT 
T 
plf42 -113 T A AT 
mrp3 ACTTAACCCT GAGGGAAAAA TAATGGAAAT TA 
plfl49 A T CA 
Oligonucleotides 
-186 -167 
FRE 5' CTATA TCAGTGAATC TAAAA 3' 
mlFRE 5' CTATA TCAGTGAACC TAAAA 3* 
in2FRE 5' CTATA ACAGTGAATC TAAAA 3' 
P42 5' CTATA TCAGCAAACC TAAAA 3' 
P149 5' CTATA ACAGTGAACC TAAAA 3' 
Fig. 1. The mrp/ptf promoter sequences and the "mrpS unique sequence" 
(FRE). Comparison of the sequences of the mrp3, plf42, and pif149 promoters in 
the region between -353 and -81. The sequence for mrp3 is shown in full. 
Wherever variations occur between mrp3, plf42 and plf149 the bases are indicated 
in bold and the bases of plf42 and plf149 are indicated, respectively, above and 
below the mrp3 sequence. The sequence information used for this figure was 
obtained from Linzer and Mordacq (13) and Connor et al. (16). The sequence 
enclosed by dashed lines is the cGRE. Potential GATA sites and API sites are 
enclosed in boxes and marked appropriately. The shaded box encloses the 
sequence that was used as a basis for preparing oligonucleotides. The region with 
the highest density of variations within that sequence is underlined within the 
shaded sequence and In the equivalent oligonucleotide sequence in the box at the 
bottom. The bottom box contains sequences of the sense strands of the FRE, 
mutated FREs (ml FRE and m2FRE), P42 and P149 oligonucleotides. The mutated 
bases in the FREs and the bases in P42 and PI 49 that differ from the FRE are 
indicated by bold letters. 
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1.0 + 0.1 
Fig. 3. Footprint of the bFGF-responsive region of the mrp3 promoter. 
DNAsel footprint analysis of the region (-234 to -121) of the bFGF-responsive 
region of the mrp3 promoter. Lane 1 contains no protein (bFGF-stimulated 3T3 cell 
nuclear extract), lane 2 contains 5 pg of protein, lane 3 contains 15 pg of protein, 
lane 4 contains 25 |jg protein. Lane 5 contains the G + A sequencing ladder. The 
position of the FRE is indicated in brackets. 
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mrp3 
control 
plf42 
plf149 
control 
control 
bFGF 
CS 
0.0 0.5 1.0 1.5 2.0 2.5 
CAT Activity (fold/control) 
Fig. 4. The effect of growth factors and serum on expression from the three 
mip/p/f promoters. Stable transfectants made from each of the three mrp/ptf 
promoters (-1100-bp to +65-bp) were grown in DMEM containing 10% bovine calf 
serum. Three days later they were treated for 24h with bFGF-rh (1 ng/ml), PDGF-
AA (5ng/ml), or an additional 10% bovine calf serum. Control cells received the 
equivalent volume of buffer in which the growth factors were dissolved but with no 
growth factor. CAT activity and protein concentrations were measured in the cell 
lysates as described in Materials and Methods. The results are the mean of 
triplicates ± c.v. in a representative experiment. The experiment was repeated five 
times with similar results. 
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Fig. 5. FRE is specifically bound by nuclear factors from 3T3 cells. Nuclear 
extracts from bPGF-treated 3T3 cells were incubated with ^ P-labeled FRE probe 
with or without competitor DNAs. A) Competitor DNAs Included an equivalent 
concentration or 10-fold molar excess of either FRE, P42, API, or the A33T33 
double-stranded oligonucleotides. The oligonucleotides used as probes were 
annealed after being labeled. In each set of two lanes for each competitor DNA, 
the sample in the left lane contained the lower concentration of competitor DNA. 
The labeled FRE oligonucleotide was added after a 10-min incubation with the 
competitor DNAs. B) Competitor DNAs included 100-fold molar excess of either 
FRE, 3*FRE, or 5'FRE double-stranded oligonucleotides. The labeled FRE 
oligonucleotide (labeled after annealing) was added after a 20-min incubation with 
the competitor DNAs. Free DNA and protein-DNA complexes were separated by 
electrophoresis and detected by autoradiography. Lane 1, probe only; -, absence of 
competitor or nuclear extract. 
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Extract QI 3T3 cell nuclear extract 
Fig. 6. Fos and Jun are not part of the FRE-protein complex. Nuclear extracts 
from 3T3 cells were incubated for 10 min in the presence or absence of unlabeled 
AP1 or FRE oligonucleotide (100-fold molar excess) or with antibody to Jun (a-Jun) 
or Fos (a-Fos) at a final concentration of 0.1 mg/ml. The samples were then 
Incubated for 20 mIn with labeled, double-stranded FRE or API oligonucleotide. 
The free DNA and DNA-protein complexes were separated by electrophoresis and 
detected by autoradiography. 
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Probe 
Extract 
*< df '' <c ^ / 
FRE HNF-1 
- placenta fetus liver 
m !••• 
Rg. 7. Presence of FRE binding proteins in fetal development. Nuclear 
extracts were prepared from placentae, fetuses, and maternal livers taken from day 
11 pregnant mice. The extracts were incubated with radio-labeled FRE 
oligonucleotide. A 100-fold excess of unlabeled FRE (FRE) or 0.1 mg/ml antibody 
to Fos (a-Fos) was added to some reaction mixtures as indicated in the figure 
(Additions). Liver nuclear extracts were also incubated with radiolabeled HNF-1 
oligonucleotide with and without a 100-fold excess of unlabeled HNF-1 (HNF-1). 
The free ONA and DNA-protetn complexes were separated by electrophoresis and 
detected by autoradiography. 
49 
70 
TK FRE(3)TK 
Fig. 8. The FRE drives FGF-responsive transcription in a heterologous 
promoter. 3T3 cells stably transfected with heterologous FRE-TK-CAT promoter-
reporter constructs containing three (FRE3-TK) or no (TK) copies of the FRE 
sequence were tested for their level of CAT expression in the presence and 
absence of 2.5 ng/ml bFGF. CAT activity was measured in the cell lysates and 
normalized to the protein concentration in the same lysate. The values are the 
mean of triplicates in a representative experiment ± sample standard deviation. The 
experiment is one of seven with similar results. 
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Table \. Fibroblast Growth Factor-Regulated Genes Containing the FRE sequence 
Gene FRE 
name species position sequence 
mrp3 Mouse -181 ICAGIGAAIC 
92kDa type IV collagenase Mouse -54 TCACTGATTC 
stromelysin-1 Human -280 CTAGTGAATT 
stromelysin (Transin) Rat -513 TCAGTAAATC 
collagenase type 1 Mouse -611 CCACTGAATC 
cathepsin L Mouse -185 AAAGTGGATC 
stromelysin-2 Human -321 GACGTGAATT 
cathepsin B Mouse -3459 CAAGTGAATC 
tissue plasminogen activator Mouse -162 ACGGTGAATA 
tissue plasminogen activator Rat -175 ACGGTGAATA 
tissue plasminogen activator Human -101 GCTGTGAATA 
c-fos Mouse -464 ACATTGAATC 
Legend: The promoter sequences of genes that have been demonstrated to be 
regulated by bFGF were searched using the Genebank database. The bolded 
letters indicate the bases which are identical to those in the FRE. 
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CHARACTERIZATION OF THE MECHANISM OF mrp3 
PROMOTER ACTIVATION AND THE DIFFERENTIAL 
RESPONSE OF THE mrp/p/f PROMOTERS BY bFGF 
lntfX>duction 
The mitogen regulated proteln/proliferin family (MRP/PLF) is a family of 34 
kDa secreted glycoproteins encoded by several closely related genes (1-3). Based 
on sequence homology, the MRP/PLFs are members of the prolactin/ growth 
hormone gene family (2, 4). The MRP/PLFs are expressed in vivo by the murine 
placenta during mid-gestation and are secreted into the maternal blood stream (3, 
5-7). Specific receptors for the MRP/PLFs have been identified on uterine 
membrane preparations and the addition of MRP/PLFs to primary mouse uterine 
cell cultures stimulates their growth (8). MRP/PLFs also bind to the mannose-6-
phosphate receptor (9). PLF1 stimulates endothelial cell migration in culture and 
neovascularization in vivo via the mannose-6-phosphate receptor (10, 11). Addition 
of various growth factors, including basic fibroblast growth factor (bFGF) to 3T3 cell 
cultures stimulates the expression of MRP/PLFs (1, 6, 12, 13). 
Five cDNAs of the MRP/PLF family have been cloned and the proteins 
encoded by these genes are between 91-98% identical in amino acid sequence (2, 
3, 4,14, Fasset et al., in preparation). Three promoters for the mrp/ptf genes have 
been cloned which include mrp3, pff42 and plf149 (4,15). These promoters 
are 97% identical between -576 to +65. 
Basic fibroblast growth factor, also called FGF2 is a member of the fibroblast 
growth factor family. Basic FGF is ubiquitously expressed in all tissues, tumors and 
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cell lines examined (reviewed in 16). It has many biological roles including 
induction of ventral mesoderm, neovascularization, wound healing, cell proliferation 
and cell migration (reviewed in 17). Basic FGF and its receptors are found in the 
placenta, the same tissue that produces MRP/PLF in vivo (18,19). The addition of 
bFGF to mouse blastocysts in culture enhances trophoblast outgrowths (20). 
Although bFGF has many important biological roles, little is known about how it 
regulates gene expression. 
Basic FGF is a potent inducer of MRP/PLF and its mRNA in 3T3 cells (1,4, 
12,14). This process depends on protein synthesis (1, 21). Addition of bFGF to 
polyploid giant cells increases mrp/plf mRNA production in trophobasts which 
produce large amounts of MRP/PLFs in vivo (22). Of the three known mrp/plf 
promoters, only mrp3 is transaiptionally activated by bFGF (Mohideen, et al., 
chapter two). Promoter deletion analysis demonstrated the bFGF responsive 
region in mrp3 lies between -353 and -81 upstream of the transcriptional start site. 
Analysis of the three promoters in this region led to the identification of a 20bp 
transcriptional element that specifically binds nuclear proteins and, when placed in 
three tandem repeats upstream of a minimal thymidine kinase promoter, is 
transcriptionally active and responsive to bFGF. This element is termed the FRE for 
bFGF response element. 
The high degree of identity between the three m/p/p/f promoters and the 
observation that only one is stimulated by bFGF provides an ideal system to study 
the mechanism of bFGF-stimulated gene expression. Here we demonstrate the 
sequence between -186 to -167 of the three mrp/plf promoters is differentially 
regulated by bFGF in a TK fusion promoter. Characterization of the 32-37 kDa 
protein(s) which bind these sequences suggest that different high affinity binding 
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proteins bind to these different sequences. 
Materials and Methods 
Plasmid constructs. The pFRE(3)TKCAT, pmFRE(3)TKCAT, 
pP149(3)TKCAT. pP42(3)TKCAT, p3'FRETKCAT, p3'FRE(3)TKCAT 
p3'P149(3)TKCAT and p3'P42(3)TKCAT plasmid constructs were prepared by 
ligating ds oligonucleotides containing a 5' Hindlll overhang and a 3' Xbal site to the 
pt18TKCAT vector cut with Hindlll and Xbal. The double stranded oligonucleotides 
inserted into the vector were; 3 tandem copies of either the FRE, mFRE, P149 or 
P42 oligonucleotide sequence corresponding to nucleotides -167 to -186 of the 
mrp3, plf149 or plf42 promoters, to make pFRE3TKCAT, pP149(3)TKCAT, 
pP42(3)TKCAT respectively, or one or 3 tandem copies of the sequences 
corresponding to nucleotides -162 to -179 of the mrp3, plf149 or plf42 promoters to 
make p3'FRETKCAT. p3'FRE(3)TKCAT p3'P149(3)TKCAT and pP42(3)TKCAT. 
Note the mFRE sequence contains a point mutation in the FRE, the T at -173 is 
changed to C. The plasmid pt18TKCAT includes the -109-bp to +51-bp sequence 
of the Herpes Simplex Virus thymidine kinase promoter upstream of the CAT gene 
and was a gift from Dr. S. Tapscott (Fred Hutchinson Cancer Research Center, 
Seattle, WA). The double stranded oligonucleotides containing one (FRE) or three 
(FRE3) tandem copies of the FRE sequence corresponding to nucleotides -167 to 
-186 of the mips promoter were also used to make plasmid constructs which 
contained -81 to +65 bp of the mrp3 promoter linked upstream of the pCATbasic 
vector (Promega, Madison, Wl). Briefly, the plasmid pmrp3(-353/+65)CATbasic 
(Mohideen, et al., chapter two), was cut with Hindlll and Sal I to isolate the -353/+65 
mrp3 insert from the vector. The -353/+65 Fragment was further cut with Alflll to 
isolate the Alflll -81/+65 Sal I mrp3 Fragment. A three part ligation containing the 
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double stranded oligonucleotides FRE or FRE3 with 5' Hindlll and 3' Xbal ends, 
AlflH -81/+65 Sal I mrp3 Fragment, and Hindlll, Sal I cut CATbasic vector was 
performed. The ligated construct was isolated from an agarose gel, filled in using 
Klenow polymerase and then blunt-end ligated. All enzymes used were from 
Promega (Madison, Wl) or New England Biolabs (Beverly, MA). 
Cell culture, DNA transfections, and CAT assays. Swiss 3T3 cells were 
grown in Dulfc)ecco-Vogt's modified Eagle's medium (OMEM with low glucose and 
containing pyruvate) containing 10% bovine calf serum (Hyclone) and 10 U/ml each 
of penicillin and streptomydn (GIBCO/BRL, Grand Island, NY) The cells were 
maintained in a humidified atmosphere containing 10% COjand 90% air at 37®C. 
Stably transfected 3T3 cells were maintained in medium that also contained 350 
|jg/ml G418 (GIBCO/BRL). The cells were free of mycoplasma contamination as 
determined by ^ H-thymidine incorporation with autoradiography and by analysis of 
Hoechst 33258-stained cells. 
Stable transfectants were prepared by plating 3T3 cells at a density of 5 x 
10® cells per 100 mm diameter dish and cotransfecting them with 20 pg total DNA 
per dish of the reporter plasmid in combination with pRSVneo provided by Dr. R. 
Padmanhaban (University of Kansas Medical Center, Kansas City, MO), at a molar 
ratio of 5:1 (reporter plasmid;pRSVneo). Transfections were performed using 
calcium phosphate to precipitate the DNA as described by Kingston (23). Stably 
transfected cells were selected in medium containing 350 |jg/nnl G418. Control cells 
that were not cotransfected with pRSVneo did not survive the G418 selection. After 
4 to 6 weeks of selection the stably transfected cells were pooled and frozen in 
liquid nitrogen. To assay the transfected cells for bFGF induction, the cells were 
plated at 7 X 10  ^cells per 60 mm diameter dishes in DMEM containing 10% bovine 
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calf seaim. Three to 4 days later, bFGF-rh (R&D Systems Inc., Minneapolis, MN) 
was added at 2.5 ng/ml in a buffer containing 0.005% bovine serum albumin, 1.4 
mM NaCI, 50 pM KCI, 7 pM Na2HP04, 0.25 mM Tris-HCI (final concentrations). 
Control cells received only the buffer. Twenty four to 30 h later the cells were 
harvested and lysed in 0.25 M Tris CI, pH 8.0 by three freeze-thaw cycles. Lysates 
were heated to 68°C for five minutes, cooled to 4°C and then the CAT assay was 
performed by the method of Seed and Sheen (24) using ^ ^C-chloramphenicol and 
butyryl CoA. Samples were then normalized to the amount of protein determined by 
the Bradford assay using the Coomassie Plus Protein Assay Reagent from Pierce 
(Rockford, IL). 
Electrophoretic Gel Mobility Shift Assay (EMSA). Nuclear extracts from 
3T3, HeLa, and CHO cells that had been treated for 6-15h with or without 2.5 ng/ml 
bFGF-rh were prepared as previously described (Mohideen, et al., (chapter two), 
25). Binding reactions (20 pi) contained 300 pg/ml BSA, 0.5 mg/ml protein (nuclear 
extract), 60 mM KCI. 1 mM EDTA, 2 mM MgCIs, 0.1 mM PMSF, 0.3 mM DTT, 100 
pg/ml poly (dl-dC)-poly(dl-dC) (Pharmacia, Piscataway, NJ or ICN 
Pharmaceuticals, Inc., Costa Mesa, CA), 20% glycerol, 20 mM Na-HEPES, pH 7.9 
and 0.25-0.5 ng double-stranded DNA prot)e. Competitor DMAs were preincubated 
with the nuclear extract for 20 minutes on ice before adding the probe. The reaction 
mixes were incubated at 30°C for 20 min. DNA-protein complexes were separated 
from free probe by electrophoresis on 4% polyacrylamide gel (80:1 
acrylamideibisacrylamide) in Tris-glycine buffer (2.7 mM EDTA, 380 mM glycine, 
2.5% glycerol, 50 mM TrIs CI, pH 8.5). Gels were run at 10 V/cm, dried under 
vacuum, exposed to a PhosphorScreen (Molecular Dynamics, Sunnyvale, CA), and 
analyzed using ImageQuant software with a Phosphorlmager. Images were also 
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obtained by exposing the gels to Kodak X-Omat AR film at room temperature or -
70°C with an intensifying screen. 
Oligonucleotide and probes. The double-stranded PRE oligomer was 
constructed by annealing the following two oligonucleotides: 5'-CTATATCAG-
TGAATCTAAAA-3' and 5'-TTTTAGATTCACTGATATAG-3'. This sequence 
corresponds to the sequence from -167 to -186 of the mrp3 promoter sequence. 
Double-stranded oligomers corresponding to the equivalent regions of the pff42 and 
plf149 promoter sequences were constructed by annealing the P42 and PI49 
oligonucleotides (Fig. 1) with their respective complementary strands. Annealing 
was performed in STE (100 mM NaCI.I mM EDTA, 10 mM Tris CI, pH 8.0). 3'FRE, 
5'FRE (Fig. 1), 3'P149, and 3'P42 (Fig. 1), were annealed to their respective 
complementary strands. All single-stranded oligonucleotides were prepared by the 
DNA Sequencing and Synthesis Facility (Iowa State University, Ames, lA). Double-
stranded oligonucleotides were phosphorylated using T4 polynucleotide kinase 
(Promega) in the presence of [y-^P]ATP (4500 Ci/mmol; ICN Pharmaceuticals, 
Inc.), 0.1 mM EDTA, 10 mM NaCI, 10 mM MgCIs, 5 mM DTT, and 70 mM Tris CI, 
pH7.6. Unincorporated radiolabel was removed using STE SELECT-D, G-25 spin 
columns (5 Prime-3 Prime, Inc., Boulder, CO). The probes were stored in STE 
buffer at -20''C. 
Native apparent molecular weights. The molecular weights of the DNA 
protein complexes were determined by the method of Hedrick and Smith (26). The 
binding reaction containing the FRE oligonucleotide probe and 3T3 cell nuclear 
extract was resolved by eiectrophoersis through nondenaturing poiyacrylamide gels 
made with various concentrations of acrylamide. The log of the relative mobility of 
standard proteins and the shifted band was plotted against percent acrylamide. The 
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slope of the lines from the standard proteins was plotted versus their MW and this 
cxirve was used to determine the MW of the protein-DNA complex. 
UV Cross-Unking. Binding reactions for the UV cross-linking experiments 
were performed as described in the EMSAs. The reactions were then UV irradiated 
for 30-60 minutes with a 300 nm UV light source (Fotodyne, Inc., Hartland, WI) at a 
distance of about 5 cm on ice. The reactions were resolved along with prestained 
protein molecular wieght standards (BioRad Technologies, Hercules, CA) on a 10% 
SDS-polyacrylamide gel. The gel was dried and autoradiography was performed. 
Results 
Examining the protein interactions in the region of the FRE. Previous 
DNAsel footprinting studies demonstrated that the region between (-234 to -121) 
including the FRE was protected by proteins in 3T3 cell nuclear extracts. However, 
because a large region beyond the FRE was covered with the footprint, it was 
necessary to use other means to investigate the extent of sequence required for 
bFGF regulation via the FRE. Competition studies using EMSA revealed that the 
proteins that bind the FRE are bound by the 3' 2/3 of the FRE and not the 5'2/3. To 
further delineate the region around the FRE bound by the FREBP, double stranded 
oligonucleotides 5'FRE, FRE and 3'FRE (Fig. 1A) were used as probes in binding 
reactions containing nuclear proteins fi-om bFGF-stimulated Swiss 3T3 cells. Two 
shifted bands indicated by arrows were produced using the 3'FRE probe (Fig. 1B, 
lane 5, arrows A and B). The faster moving shifted band (A) migrates at the same 
rate as the band produced by the FRE. No shifted bands were observed using the 
5'FRE probe. This data indicates that more than one protein binds to the -179 to -
162 region of the mrp3 promoter and that the sequences necessary for the 
protein(s) binding to the FRE are located between -179 and -167. 
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To determine if the unique stimulation among the promoters of mrp3 
by bFGF is associated with differences in the proteins binding to the -179 through 
-162 sequences in the m/p/p/f promoters, EMSAs were performed with double 
stranded oligonucleotides corresponding to these sequences (Fig. 1A). The 3'P42 
and 3'P149 double stranded oligonucleotide probes produced two similar shifted 
bands {A &B indicated by arrows in Fig. 1B) as the 3'FRE double stranded 
oligonucleotide probe, and an additional slower migrating shifted band (C indicated 
by the arrow in Fig. IB, lanes 5. 10, 14). The protein(s) binding the 3'FRE, 3'P42 
and 3'P149 double stranded oligonucleotides were specific for their respective 
sequences as 100-fold molar excess oligonucleotides competed for proteins binding 
to the cognate oligonucleotide probe. Excess unlabeled 3'P42 or 3'P149 
oligonucleotide also competed for nuclear proteins binding to the 3'FRE 
oligonucleotide probe (Fig. 1B, lanes 8 & 9). Excess unlabeled 3'FRE 
oligonucleotide partially competed for nuclear proteins binding to the 3'P42 and 
3'P149 oligonucleotide probes producing the faster moving bands (A & B), but not 
for the slower moving band (C) (Fig. 1B, fane 13 & 17). This data suggests that the 
3'P149 and 3'P42, which include the -179 to -162 sequences in the plf149 and f3lf42 
promoters, are able to bind to an additional protein compared with the same 
sequence (3'FRE) in the mrpS promoter. This changed composition of the protein 
complex may involve a protein that is the key for the differences in the regulation of 
the three mrp/plf promoters by bFGF. Excess unlabeled FRE, P42 or PI 49 
oligonucleotides partially competed for proteins binding their respective 3' 
oligonucleotides; particularly for the proteins producing the faster moving complex, 
suggesting that the proteins binding to the FRE, P42 and P149 can also bind to the 
3'FRE, 3'P42 and 3'P149, respectively. 
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Basic FGF Activity of the sequences between '179 and -162 of tfte 
mrp/plf promoters. To determine if the sequences between -179 and -162 of the 
mrjo/ptf promoters can account for the differential regulation of these promoters in 
response to bFGF, one 3'FRE or three tandem repeats of the 3'FRE, 3'P42 or 
3'P149 were linked upstream of a minimal thymidine kinase promoter-CAT reporter 
gene and transfected into Swiss 3T3 cells. The resulting stably transfected cells 
were tested for their response to bFGF. All four of these promoter-reporter 
constructs were repressed in response to bFGF compared to the control, 
unstimulated cells (Fig. 2). However, as previously reported (Mohideen et al, 
(chapter two)), three copies of the FRE linked upstream of the minimal thymidine 
kinase promoter-CAT reporter gene was activated in stable transfectants in 
response to bFGF. This demonstrates that the region of the mrp3 promoter which is 
activated by bFGF includes the sequences between -186 to -167, but not the 
sequences between -166 to -162. 
Basic FGF Activity of the sequences between -186 and -167 of the 
mrp/plf promoters. The region between -186 and -167 of the mrp3 promoter is 
activated by bFGF. We wished to determine if differences in the sequence of this 
segment in the three mrp/p  ^promoters can account for the differential regulation of 
these promoters in response to bFGF. Three tandem repeats of the -186 to -167 
sequences in the plf42 and plf149 promoters were linked upstream of a minimal 
thymidine kinase promoter-CAT reporter gene and stably transfected into Swiss 3T3 
cells. After selection for transfected ceils, they were tested for their response to 
bFGF. As previously demonstrated, the FRE(3)TKCAT cells are activated 
approximately 2-fold in response to bFGF compared to unstimulated cells. 
However, P42(3)TKCAT and P149(3)TKCAT cells are not stimulated by bFGF (Fig. 
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3A). This data Indicates that the FRE(3) sequence confers bFGF activation when 
linked to a heterologous promoter but the P42(3) and P149(3) do not. These results 
suggest that the differences in the sequence between -186 to -167 of the mrp/ptf 
promoters may account for their differential regulation by bFGF. 
To determine if the FRE is responsible for the bFGF stimulation of the 
homolgous mrp3 promoter, one and three tandem repeats were linked upstream of 
the minimal mrp3 promoter -81 to +65-CATbasic reporter gene, stably transfected 
into Swiss 3T3 cells and tested for their response to bFGF (Fig. 3B). The 
/77/p3(-81/+65) promoter construct alone is repressed by bFGF as previously 
demonstrated (Mohideen, et al., chapter two). The addition of one FRE directly 
upstream of the -81/+65 mrp3 promoter was not significantly different in Its response 
to bFGF from the -81/+65CATBasic construct. However, the addition of three 
copies of the FRE directly upstream of the -81/+65 mrp3 promoter causes activation 
(added onto a suppression due to the -81/+65) by bFGF and this activation is 
exactly 2-fold as similarly shown with the FRE(3)TKCAT construct. This data 
demonstrates that the FRE and the protein(s) binding to it are stimulated by bFGF, 
activating expression 2-fold which counter acts or negates the 2-fold repression 
caused by bFGF in the mrp3{-BM+65) promoter. 
Mutation in FRE results in diminished bFGF responsiveness. To 
determine whether the unique base in the FRE sequence (T at position -173) 
contributes to the responsiveness of this element to bFGF, we mutated this base to 
a C which is the base found in this position in the plf149 and plf42 promoters. The 
mFRE(3)TK constructs were tested for their responsiveness to bFGF in stable 
transfectants. The results show that the FGF responsiveness of the 
mFRE(3)TKCAT construct is diminished with respect to the FRE(3)TK construct 
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(Fig. 4). Whereas the differences between bFGF treatment and control treatment 
(no bFGF) was statistically significant to p<0.005 for the FRE(3)TKCAT, the bFGF 
response of the mFRE(3)TKCAT was not statistically significant. Thus, mutation of 
the FRE at the unique position, -173, results in a debilitated bFGF response 
element. 
RelativB binding affinities for the proteins binding to the FRE, P149 and 
P42 oligonucleotides. Because our results suggested that the three mrp/plf 
sequences corresponding to the FRE bind to different proteins, the relative affinities 
of the proteins binding the FRE, P149 and P42 oligonucleotides were measured by 
competition assays. The FRE, PI 49 or P42 double stranded oligonucleotides were 
used as a probe with increasing concentrations of unlabeled FRE, PI 49 and P42 
double stranded oligonucleotides. Cognate oligonucleotides were the most 
effective competitors (Fig. 5). These results suggest that multiple proteins can bind 
to these related sequences and that the protein binding with the highest affinity for 
each oligonucleotide is different. 
Off'Rates of proteins binding to the '186 to -167 sequences of the ptf42 
and plf149 promoters. The results of the competition studies suggested that the 
rate of dissodation of the protein DNA complex might be quite slow for P149 as 
40% of the proteins bound to PI49 remained even at 25-fold excess 
oligonucleotide. Therefore, we determined the off-rates of the proteins bound to 
P149 and P42 by mobility shift assay after adding 200-fold excess of the cognate 
unlabeled competitor oligonucleotide for various amounts of time (Fig. 6). The 
proteins dissociating from the P42 and PI49 probes exhibit a triphasic curve. Fifty-
four percent of the total proteins t)ound to P42, while only 17.5% of the total 
proteins bound to PI 49 dissociate with a t^ j^ than the time it takes the 
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proteins to run into the gel (approximately five min.)- Thirty-six percent of the total 
proteins bound to P42 dissociate with a ti/2 of 7 min, while the remaining 10% 
dissociate with a t /^s of greater than 40 min. Fifty-five percent of the total proteins 
bound to PI 49 dissociate with a of 12.5 min and the remaining 27.5% dissociate 
with a ti/2 of greater than 40 min. These studies demonstrate that the proteins 
bound to PI 49 are tightly bound and under the conditions of the competition 
studies, 20 minutes does not allow for the majority of the proteins bound to PI 49 to 
reach equilibrium. This data also demonstrates a difference in the binding affinity 
between proteins bound to the P42 versus PI49 oligonucleotide probes. 
Characterization of the protein(s) bound to the sequences -186 to -167 
and '179 to -162 of the mrp/ptf promoters. The protein complex formed on the 
PRE was investigated further, first to determine its apparent native molecular weight 
and second to determine the apparent molecular weights of the proteins directly 
associated with the DNA. The apparent native molecular weight of the proteln-DNA 
complex formed with the PRE oligonucleotide, determined according to Hedrick and 
Smith (26), was approximately 60 kDa. (Fig. 7A). This data suggests the protein 
component of the complex is a mass of about 47 kDa. 
The protein(s) directly bound to the DNA were covalently linked by UV 
cross-linking to oligonucleotides corresponding the mrp3 promoter between -186 to 
-167 (PRE) and -179 to -162 (3'FRE). The proteln-DNA adducts were resolved by 
SDS-PAGE. Two to three bands ranging from 45-50 kDa were detected for both 
the FRE and 3'FRE probes used, dependent on both UV light and addition of 
nuclear extract (Fig. 7B). Subtracting the molecular weight of the oligonucleotides 
yielded a range of proteins from 32 to 37 kDa. An additional band was observed 
with the 3'FRE oligonucleotide detected at 70 kDa that corresponded to a protein(s) 
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of 58 kDa. That excess unlabeled oligonucleotides added to the reaction mixture 
competed for these bands demonstrates specificity of the cross-linked products. 
Proteins UV cross-linked to P149, P42, 3'P149 and 3'P42 oligonucleotide probes 
demonstrated a banding pattern similar to the FRE (data not shown). From these 
results we conclude that a protein of 32 to 37 kDa binds directly to each of the 
mrfi/pff promoter sequences. The higher mass of the native complex suggests that 
there might be another 10 kDa component of the complex, perhaps a small protein 
that does not directly interact with the DNA. This third component might be part of 
the 70 kDa band observed with the 3'FRE. 
Nuclear proteins binding to the FRE are present in human cells. Protein 
nuclear extracts from HeLa cells and CHO cells were tested for their ability to bind 
to the FRE (Fig. 8). Both HeLa cells and CHO cells contain nuclear proteins that 
bind the FRE and are competed for by excess unlabeled FRE double stranded 
oligonucleotide. This data demonstrates that proteins that bind the FRE are 
present in the human and hamster as well as the mouse. 
Nuclear proteins bound to the FRE also bind to sequences similar to 
the FRE found in stromelysin and collagenase gene promoters. The rat and 
human stromelysin and the mouse collagenase gene promoters are regulated by 
bFGF and contain a sequence similar to the -181 to -172 region of the FRE. Double 
stranded oligonucleotides corresponding to the FRE-like sequence in these 
promoters were used as competitors to determine if they could bind to the proteins 
bound by the FRE. All three double stranded oligonucleotides (rStrom, hStrom, and 
mCol) competed for proteins binding to the FRE (Fig. 9). When used as probes, 
proteins in HeLa cell nuclear extracts bind to the rStrom and hStrom 
oligonucleotides and are competed for by excess uniat>eied cognate double 
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stranded oligonucleotides as well as FRE. The mCOL oligonucleotide probe did not 
bind to specific nuclear factors (data not shown). This data suggests the possibility 
that the proteins binding to the FRE which regulate mrp3 gene expression in 
response to bFGF may also regulate the expression of the stromelysin-1 and 
coHagenase genes. 
Discussion 
The expression of genes is a balance between repressors and activators 
regulated by various cytokines and growth factors effecting transcription. Three 
identified promoters are 97% identical in sequence, yet are differentially 
regulated by bFGF. The mrp3 promoter was activated by bFGF while the plf42 and 
ptf149 promoters did not respond to bFGF when -1100bp were tested (Mohideen, et 
a!., chapter two). Thus, the promoters provide an excellent system to study 
the effects on transcriptional regulation by bFGF. 
We previously identified a bFGF response element (FRE) located -186 to 
-167 of the mrp3 promoter (Mohideen, et al., chapter two). Promoter constructs 
containing three tandem copies of the P42, P149 and FRE oligonucleotides linked 
to the minimal thymidine kinase promoter-CAT reporter construct stably transfected 
into 3T3 cells revealed differences in their response to bFGF. While FRE(3)TKCAT 
cells are transcriptionally activated in response to bFGF, P42(3)TKCAT and 
P149(3)TKCAT cells are not regulated by bFGF. This data indicates that the 
FRE(3) sequence can confer bFGF responsiveness when linked to a heterologous 
promoter but the P42(3) and P149(3) cannot. This suggests that different proteins 
may be able to bind to these similar sequences in response to bFGF. Alternatively, 
the same protein binds to these similar sequences but with different affinities or in a 
different conformation in response to bFGF. 
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Similar shifted bands are observed when the PRE. P42 or P149 
oligonucleotides were used as probes. Mobility shift assays also demonstrated that 
nuclear proteins from 3T3 cells bound the PRE and were competed for by excess 
unlabeled P42 and P149 oligonucleotides. But the latter two oligonucleotides were 
less efficient competitors than the FRE. Competition studies with each of the 
oligonucleotides as probes and as competitors showed that the cognate 
oligonucleotide was always the most effective competitor. The complexes 
demonstrated several dissociation rates for the P42 (dissociation of proteins for P42 
and FRE were similar in off rate studies using 25-fold competitive oligonucleotides, 
data not shown) but quite different for P149. Unlike the complexes formed on the 
P42 oligonucleotide, about 28% of the complexes involving P149 dissociate very 
slowly with a half-life of greater than 40 min. In comparison, only 10% of the 
complexes involving the P42 dissociate with a half-life of over 40 min. These 
results suggest a difference in the interaction of proteins which bind P149 versus 
P42; either the same proteins interact with all three promoters but in a different way 
or different proteins are involved in the formation of these complexes on each 
oligonucleotide. 
Further characterization of the proteins that bind the FRE, P149 and P42 
oligonucleotides demonstrated these protein-DNA UV cross-linked complexes have 
an approximate MW of 45-50 kDa which is 10 to 15 kDa different than the average 
MW of the native complex. However, the range of the MW of the native complex in 
the Hedrick-Smith analysis was 50-70 kDa. The difference in the native MW of the 
complex compared to the UV cross-linked complex could be due to the nature of the 
method. This suggests that a single protein is bound to each oligonucleotide in the 
shifted complex. Alternatively, the higher mass of the native complex suggests that 
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there might be another 10 kDa component of the complex, perhaps a small protein 
that does not directly interact with the DNA. 
The protein(s) that bind the FRE appear to be binding to the 3*2/3 of the FRE 
(-179 to -167) because the 5'FRE oligonucleotide containing sequences from -191 
to -171 of the mrp3 promoter did not bind proteins in 3T3 cell nuclear extracts. The 
FRE competes for the proteins that bind to the 3'FRE oligonucleotide probe. 
However, more shifted complexes are observed with the 3'FRE than with the FRE. 
Thus, although the 3'FRE probe binds the FREBP, the complex formed by the 
3'FRE contains added components, perhaps another protein. 
The FRE sequence (-186 to -167) of the mrp3 promoter is a transcriptional 
activation element and responsive to bFGF in the context of a minimal heterologous 
promoter. When placed upstream of the -81/+66 segment of the mrpS promoter, it 
also causes transcriptional activation (added onto a suppression due to the 
-81/+65) by bFGF. This activation is exactly 2-fold as similarly shown with the 
FRE(3)TKCAT constructs. This data demonstrates that the FRE and the protein(s) 
binding to it are stimulated by bFGF, activating expression 2-fold which counter acts 
or negates the 2-fold repression caused by bFGF in the m/p3(-81/+65) promoter. 
Several transcriptional elements have been identified in the mrp/plf 
promoters within the -353 to -81 base pair region. These include the API sites 
located -231 to -224 and the Sph repeats from -219 to -205 upstream of the 
transcriptional start site and the cGRE/negative regulatory element (27). As we 
have previously demonstrated (see chapter two), API proteins are probably not 
involved with the bFGF activation of the mrpS promoter. Preliminary data suggests 
that the cGRE/negative regulatory element is also not involved in the activation of 
the mrpS promoter fc}ecause addition of dexamethasone to the (-681/+65)CATBasic 
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cells does not alter their ability to tie activated by bFGF (data not shown). 
Deletion of GATA transcription factors have been shown to decrease the 
activity of the mrp/plf genes in vivo (28). A putative GATA site is present at the 5' 
end of the FRE sequence in the mrp3 and plf42 promoters. Gel mobility shift 
assays demonstrate that the 5'FRE oligonucleotide which contains this putative 
GATA site within the FRE did not produce a shifted band, indicating that nuclear 
proteins from 3T3 cells do not bind to this element. Other GATA sites on the mrp/plf 
promoters are located outside the FRE sequence and are all conserved amongst 
the three promoters. Thus, it is unlikely that the regulation of mrp3 expression by 
bFGF is mediated by a GATA transcription factor. 
There was no reproducible difference in the proportion of shifted 
oligonucleotide when nuclear extracts from bFGF-stimulated cells were compared 
with nuclear extracts from unstimulated control cells. Thus, regulation by bFGF of 
the FRE is probably not mediated by changing the amount of FREBP associated 
with the FRE. Rather, the bFGF stimulation may cause a conformational change or 
protein modification such as phosphorylation to activate the protein binding to the 
FRE, which can then activate gene expression. The presence of FREBPs in HeLa 
and CHO ceils as well as 3T3 cells demonstrates these proteins are not cell-type 
specific but are found endogenously in a number of cells. 
We found a sequence similar to the (-181 to -172) FRE sequence upstream 
of the coding sequences in several other genes regulated by bFGF using the GCG 
database search program. Proteins bound to the FRE could be competed off by 
these sequences from the human and rat stromelysin-1 gene and the mouse 
co/lagenase type-1 gene promoters. The rat and human stromelysin sequences 
bound specific proteins in bFGF-stimulated nuclear extracts that could be competed 
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for by the FRE. This data suggests that the proteins binding to the FRE that 
regulate mrp3 gene expression in response to bFGF may also regulate the 
expression of the stromelysin-1 gene. 
Based on these studies, we propose that the element responsible for the 
regulation by bFGF of the mrp3 promoter is the sequence between -186 to -167, the 
FRE. As we have demonstrated, the FRE is a transcriptionally active, bFGF 
responsive element in the context of three tandem repeats in either a heterologous 
promoter (TKCAT) or a homologous promoter ((-81/+65)CATBasic). Furthermore, 
the differential regulation of the mrp/p/f promoters in response to bFGF is due to the 
differences in sequence of the three promoters between -186 to -167 as determined 
in the heterologous promoter-reporter studies. Competition studies suggest that the 
proteins which bind to these different sequences with the highest affinity are 
different proteins, which may allow for this differential regulation by bFGF. 
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Fig. 1. Differential complexes formed on the -179 to -162 sequences of the 
mrp/ptf promoters and the sequences surrounding the FRE. A. Sequences of 
the sense strands of the 5'FRE, FRE, 3'FRE, P149, 3'P149, P42, and 3'P42 
oligonucleotides, corresponding to the indicated sequences in the mrp3 (FRE), 
plf149, (P149) and ptf42 (P42) promoters. The bases in the oligonucleotides which 
differ tjetween the three mrp/p/f promoters are bolded and underlined. The bases 
between -186 and -167 of the three promoters are capitalized. The sequence 
information for this figure was obtained from (4, 15). B. An electrophoretic gel 
mobility shift assay using nuclear extracts from bFGF-treated 3T3 cells pre-
incubated with or without 10OX molar concentration of unlabeled double stranded 
oligonucleotides (as indicated by competitor) and then incubated with ^ P-labeled 
probe (5'FRE, FRE, 3'FRE, 3'P149 or 3'P42 double stranded oligonucleotide). 
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Fig. 2. The sequences between -ITS and -162 of the mrp/pff promoters 
repress transcription of a heterologous promoter in response to bFGF. 3T3 
cells stably transfected with FRE(3), 3'FRE, 3'FRE(3), 3'P149{3), or 3'P42(3)TK-
CAT promoter-reporter constructs were tested for their level of CAT expression in 
the presence and absence of 2.5 ng/ml bFGF. CAT activity was measured in the 
cell iysates and the results were normalized to the protein concentration in the same 
lysate. The values are the fold over control of the means of multiple experiments ± 
standard deviation. A t test was performed comparing the constructs with TKCAT, 
N=5: FRE3, N=4, p<0.02; 3'FRE, N=4, p<0.1; 3'FRE(3), N=5. p<0.01; 3'P42, 
N=5, p<0.001; 3'P149, N=4, p<0.CX)25. The range of normalized activity of control, 
unstimulated cells in cpm/mg protein are; FRE(3), (143,879 - 710,379); 3'FRE, 
(12,861 - 35,346); 3'FRE(3), (21,719 - 51,880); 3'P42, (62,180 - 95,700); 3'P149, 
(25,818 - 73,551); TKCAT. (4,314 -18,722). 
Fig. 3. The sequences between -186 and -167 of the mrp/plf promoters 
differentially regulate transcription in response to bFGF. 3T3 cells stably 
transfected with heterologous or homologous promoter-reporter constructs were 
tested for their level of CAT expression in the presence and absence of 2.5 ng/ml 
bFGF. CAT activity was measured in the cell lysates and normalized to the protein 
concentration in the same lysate. A. Cells stably transfected with either FRE(3), 
P149(3), or P42(3)TK-CAT promoter-reporter constructs containing three or no 
copies of the FRE, P149 or P42 sequence . The values are the fold over control of 
the means of multiple experiments ± standard deviation. A t test was performed 
comparing the constructs with TKCAT, N=5; FRE, N=4, p<0.02; P42, N=3, p<0.1; 
P149, N=2, p<0.25. The range of normalized activity of control, unstimulated cells 
in cpm/mg protein are: FRE, (143,879-710,379); P42, (810-4,790); P149, (11,767 
- 18,995); TKCAT, (4,314 - 18,722). B. Cells stably transfected with either one, 
three, or no copies of the FRE linked to the mrp3(-81/+65)-CATbasic promoter-
reporter construct or the mrp3(-681/+65)-CATbasic promoter-reporter construct. 
The values are the fold over control of the means of multiple experiments ± 
standard deviation. A t test was performed comparing the constructs with (-
81)CATbasic, N=10; (-681), N=13, p<0.0005; FRE, N=4, p>0.25; FRE(3), N=6, 
p<0.05. The range of normalized activity of control, unstimulated cells in cpm/mg 
protein are: (-681), (1,327-24,079); FRE(3), (9,149 - 26,632); FRE, (1,001 - 1,696); 
(-81), (7,305-31,705). 
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Fig. 4. BFGF stimulation of FRE(3)TKCAT is diminished in the 
mFRE(3)TKCAT cells. 3T3 cells stably transfected with FRE{3)TKCAT or 
mFRE(3)TKCAT promoter-reporter constructs were tested for their level of CAT 
expression in the presence and absence of 2.6 ng/ml bFGF. CAT activity was 
measured in the cell lysates and the results were normalized to the protein 
concentration in the same lysate. The values are the fold over control of the means 
of triplicates for each experiments A paired t test was performed for each set of 
data comparing the control, unstimulated cells with the bFGF-stimulated cells. 
FRE(3), N=16; mFRE(3) N=10. The range of normalized activity of control, 
unstimulated cells in cpm/mg protein are: FRE(3), (12,470 - 710,379); mFRE(3), 
(2,637 - 677,876). 
Fig. 5. Relative affinities of the nuclear proteins binding the FRE, P42 and 
P149 double stranded oligonucleotides. A. An electrophoretic mobility shift 
assay using the FRE probe with bFGF-treated 3T3 cell nuclear extracts. The 
extract was incubated without competitor {lanes 1, 2, and 7) or with increasing 
amounts (lane 3,1X: lanes 4 and 8, 2.5X; lanes 5 and 9, 5X; lanes 6 and 10, 10X; 
and lane 11, 25X) of unlabeled double stranded FRE {lanes 3-6) or P42 {lanes 8-
11) oligonucleotides. Similar experiments were performed with P149 as a 
competitor, and P42 and P149 replacing the FRE as the probe (not shown). B. 
quantitation of the binding of nuclear proteins to the FRE, P42 or P149 as a probe 
in the presence of the indicated competitors relative to no competitors (control). 
The data are the means and standard deviations of two to five independent 
experiments. 
78 
Competitor 
1 2  3 4  5 6 7 8 9  1 0  1 1  
FRE P149 P42 
^120-
0 5 10 1S 20 25 
n<io unlabeled cuiiipeltoi/labaled FRE 
PI 49 FRE P42 
20-
0 5 10 15 20 25 
ntio unlabeled conpetitor/latMled PI 49 
-- plK2 FRE pin4S 
^ 120-
20-
3 S 10 15 20 25 
ratio unlabeled oompetitorAabeled P42 
79 
100^ 
o) : \\ 
—  "  \ \  c V \ 
'm r \ •— 
0 10 20 30 40 
time (min) 
Fig. 6. Off Rates of proteins binding to P42 and P149 oligonucieotide probes. 
An electrophoretic mobility shift assay was perfomied using P42 (open circles) or 
P149 {dosed drdes) oligonucleotide probes. Binding reactions contained no 
competitor (control) or 200-fold excess unlabeled cognate oligonucleotides added at 
various times after the 20 min incubation with the probe. The amount of 
undissociated protein-DNA complexes, measured using a phosphoimager 
(Molecular Dynamics), was plotted against the time the competitor was included. 
The dashed lines represerrt the linear regression of the points included to determine 
the ti;2 of the dissociation of the complexes, P42; t1/2 = 7 min , P149: t1/2 = 12.5 
min. 
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Fig. 7. Molecular weight determination of the protein-DNA complex of the 
FRE oligonucleotide. A. The Hedrick-Smith (26) method was used to determine 
the native MW of the protein-DNA complex formed on the FRE and 3'FRE 
oligonucleotides (see materials and methods). B. Binding reactions containing 
bFGF-stimulated 3T3 cell nuclear extracts preincubated with and without 100-fold 
molar excess of the indicated double stranded oligonucleotides and then incubated 
with probe were UV cross-linked and resolved on a SDS-polyacrylaminde gel. As 
controls, the nuclear extract (/ane 1) and UV light {lane 2) were omitted. The 
apparent sizes of the molecular vy '^eght standards (prestained markers, Bio-rad) are 
indicated. 
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Fig. 8. Nuclear proteins recognizing the FRE are found in CHO and Hel-a 
cells. An electrophoretic mobility shift assay using the FRE probe with bFGF-
treated 3T3 cell, CHO cell or HeLa cell nuclear extracts pre-incubated with or 
without 100X molar concentration of unlabeled FRE double stranded 
oligonucleotides (as indicated by competitor). 
Fig. 9. Nuclear proteins bound to the FRE also bind to sequences similar to 
the FRE found in stromelysin and collagenase gene promoters. A. Sequences 
of the sense strands of the FRE, rStrom, hStrom and mCol oligonucleotides, 
corresponding to the indicated sequences in the mrp3 (FRE), rat Stromelysin-1 
(rStrom), human Stromelysin-1 (hStrom) and mouse interstitial collagenase (mCol) 
promoters. The bases between -181 and -172 of the mrp3 promoter are underlined 
and bolded. The bases identical to the FRE in the other oligonucleotides within the 
underlined region are bolded. The sequence information for this figure was obtained 
from (29,30) B. An electrophoretic gel mobility shift assay using nuclear extracts 
from bFGF-treated Hela cells pre-incubated with or without 100-fold molar ratio of 
unlabeled double stranded oligonucleotides (as indicated by competitor) and then 
incubated with ^ P-labeled probe (FRE, rStrom or hStrom double stranded 
oligonucleotide). 
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GENERAL CONCLUSIONS 
The focus of this research was to eluddate the mechanism(s) by which bFGF 
regulates mrp/plfgene expression. MRP/PLFs are a family of glycosylated proteins 
which function as angiogenic factors, stimulate murine uterine cell growth, and 
inhibit muscle specific differentiation (21, 24). MRP/PLFs are expressed in vivo in 
the trophoblastic giant cells of the murine placenta (17). Basic FGF is a ubiquitous 
growth fector and is expressed in a wide range of tissues and organs including the 
murine placenta (reviewed in 40-42, 58). It elicites its response through specific 
FGF receptors activating a signal transduction cascade which ultimately ends in the 
regulation of gene expression. Many genes are regulated by bFGF, but the signal 
transduction pathways eliciting the bFGF response are still largely unknown. By 
studying the mechanism(s) of mrp/pff gene expression by bFGF, we can learn more 
about the mechanism by which bFGF regulates gene expression. 
Summary of Results and Discussion 
Previous results demonstrated that one of the known mrp/plf gene promoters, 
mrp3, is transcriptionally activated by bFGF (see first paper, chapter two). Deletion 
analysis of the mrp3 promoter identified the bFGF responsive region to lie between 
-353 and -81 bp upstream of the transcriptional start site. An element (which we 
have termed the FRE (for bFGF response element)) was identified that contains a 
unique base pair in the mrp3 promoter which binds to specific proteins from 3T3, 
CHO and Hela cell nuclear extracts as demonstrated by mobility shift assays. We 
hypothesized that the protein(s) binding to this element is a transcription factor(s) 
which could regulate mfj)3 gene expression when stimulated by bFGF. To test this 
hypothesis one, two and three copies of the FRE (FRE1, 2, and 3) were linked 
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upstream of a minimal thymidine kinase promoter-CAT reporter gene. Although all 
three of these constructs drove expression of the CAT reporter gene at a rate of 10-
200X that of the basal TK promoter alone, only the FRE3 plasmid construct was 
stimulated by bFGF. This demonstrates that the PRE is a transcriptional element 
and can be regulated by bPGP. 
To characterize the protein(s) binding to the PRE, competition studies were 
performed using the mobility shift assay. Excess unlabeled AP1 oligonucleotide did 
not comp)ete for protein(s) binding to the PRE. The addition of antibodies directed 
against either the c-Jun or c-Pos protein families had no effect on the proteins 
binding to the PRE indicating that the AP1 transcription factors were not involved 
with the protein{s) binding to the PRE. Functional analysis of the mrp/pff promoters 
demonstrated that only mrp3 was activated by bPGP and that serum or PDGF did 
not effect the activity of any of the mrp/ptf promoters. Furthermore, down regulation 
of protein kinase C (PKC) by phorbol esters did not alter the bPGP activation of the 
mrp3{-353/+65) promoter. As both serum and PKC can activate Jun and Fos 
transcription factors, this data provides further evidence that activation of the mrp3 
promoter by bPGF does not involve AP1 proteins. It also suggests that the signal 
transduction pathway used by bPGF to activate mrp3 gene expression is unique 
from the pathways turned on by serum and PDGF. 
A putative GATA site was found in the 5'2/3 of the PRE and tested for its 
ability to bind nuclear proteins from bPGF-stimulated 3T3 cells. The 5'PRE (-191 to 
-175) oligonucleotide which contains this putative GATA site could not compete for 
proteins bound to the PRE, nor could it produce DNA-protein complexes when used 
as a probe in binding reactions. The data suggests that a GATA factor is not 
involved in bPGP stimulation of transcription mediated by the PRE. 
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As the DNA footprint showed that sequences surrounding the PRE were 
bound by protein, the 3'PRE (-179 to -162) was used as a probe to determine if the 
proteins that bind the PRE could also bind this sequence and we could thus narrow 
down the sequence these proteins bound to. While the 3'PRE could produce a 
shifted band similar to the PRE and was competed for by the PRE, functional 
analysis of the 3'PRE in a TKCAT fusion construct demonstrated that bPGP did not 
activate this sequence. Thus the protein(s) that bind the PRE can bind between 
-179 to -167, and the bPGP-activated activity of this protein uses -186 to -167, but 
not-166 to-162. 
Excess unlabeled oligonucleotides containing the respective sequences in 
the pff149 (PI 49) and pff42 (P42) promoters, the same site as the PRE, 
demonstrated partial competition for proteins binding to the PRE, while excess 
unlat)eled PRE exhibited much greater competition at the same molar ratio. The 
PI 49 and P42 oligonucleotides used as probes exhibited a similar shifted band 
pattern as that for the PRE oligonucleotide. A series of competition studies were 
performed in which increasing molar concentrations of unlabeled PRE, PI49 and 
P42 oligonucleotides were included in the binding reaction containing the different 
oligonucleotides as prot>es. The results demonstrate that the cognate 
oligonucleotide was the most effective competitor, while the other two unlabeled 
olignucleotides were less efficient competitors. While the dissociation studies 
show that the majority of the proteins bound by PI 49 do not dissociate completely 
during the time these competition studies were done, P42 and PRE do, suggesting 
a difference in the interaction of proteins which bind PI 49 versus P42 and PRE. 
The dissociation studies validate the competition studies for the P42 and PRE 
oligonucleotide probes which suggests that multiple proteins can bind to these 
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related sequences and that the protein binding with the highest affinity for each 
oligonucleotide is different. 
To determine if the differences in sequence between (-186 to -167) of the 
mrp/plf promoters are in part responsible for their differential regulation by bFGF, 
three tandem repeats of P42 and P149 oligonucleotides were linked upstream of a 
minimal thymidine kinase promoter-CAT reporter gene and transfected into Swiss 
3T3 cells. FRE(3)TKCAT cells were stimulated by bFGF, however, 
P42(3)TKCATcells and P149(3)TKCAT cells were not regulated by bFGF. This, 
with data from the electrophoretic mobility shift assay, suggests that different 
proteins may bind to these similar sequences in response to bFGF. Alternatively, 
the same protein is able to bind to these similar sequences but with different 
affinities or in a different conformation in response to bFGF. 
To determine if the FRE is responsible for the bFGF stimulation of the 
homolgous mrp3 promoter, one and three tandem repeats of the FRE were linked 
upstream of the minimal mrp3 promoter -81 to +65-CATbasic reporter gene, 
transfected into Swiss 3T3 cells and tested for their response to bFGF. The 
m/p3(-81/+65) promoter construct alone is repressed by bFGF. The addition of 
three copies of the FRE directly upstream of the -81/+65 mrp3 promoter causes 
activation (added onto a suppression due to the -81/+65) by bFGF and this 
activation is exactly 2-fold as similarly shown with the FRE(3)TKCAT constructs. 
This data demonstrates that the FRE and the protein(s) binding to it are stimulated 
by bFGF, activating expression 2-fold which counter acts or negates the 2-fold 
repression caused by bFGF in the m/p3(-81/+65) promoter. 
Based on these studies, we propose a model for the activation of gene 
expression of the rnipS promoter by bFGF. The element responsible for the 
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stimulation of the mrp3 promoter by bFGF is the sequence between -186 to -167, 
the PRE. As we have demonstrated, the PRE is a transcriptionally active, bPGP 
responsive element in the context of three tandem repeats in either a heterologous 
promoter (TKCAT) or a homologous promoter (-81/+65)CATBasic). Furthermore, 
the differential regulation of the promoters in response to bPGF is due to the 
differences in sequence of the three promoters between -186 to -167 as determined 
in the heterologous promoter-reporter studies. Competition studies suggest that the 
proteins which bind to these different sequences with the highest affinity are 
different proteins, which may allow for this differential regulation by bPGF. 
A search of genes containing a sequence similar to the PRE include both the 
rat and human stromelysin gene promoter, the mouse coHagenase type-1 gene 
promoter, and the tissue type plasminogen activator gene promoter among others. 
Gel mobility shift assays demonstrated that the FRE-like oligonucleotides for the rat 
and human stromelysin as well as that for the mouse collagenase gene competed 
for proteins which bind the PRE. When the rat and human stromelysin 
oligonucleotides were used as probes, a shifted band was observed that migrated a 
similar distance as the proteins which bind the PRE. Although the previously 
Identified PGP response elements for the collagenase gene does not include the 
PRE like sequence (48), it does not rule out a possible role for this PRE-like 
sequence in the regulation of the mouse collagenase gene, or the rat and human 
stn)melysin genes in response to PGP in vivo. 
The proteins that bind to the PRE are also found in nuclear extracts prepared 
from murine day 11 placentae and embyros but not maternal liver suggesting that 
they play a key role in the regulation of gene expression in growing and 
differentitating tissue. The MRP/PLPs and the two proteases Interstitial 
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Collagenase Type I and Stromelysin-I are believed to be involved in tissue growth 
and remodeling. The MRP/PLFs have the demonstrated functions of stimulating 
angiogenesis (21) and uterine cell proliferation 24) and inhibiting myoblast 
differentiation (25). The presence of the FRE sequence in the promoters of other 
genes that also encode proteins involved in tissue growth and remodeling and the 
presence of the proteins that bind the FRE in growing and differentiating tissue 
suggests that the FRE and the proteins that bind to it may be the means by which 
several genes are regulated by bFGF. 
Future Directions 
There are many experiments that can be done to further characterize the 
proteins binding to the FRE, P149 and P42 sequences to further elucidate the 
mechansim by which the mrp/plf gene promoters are differentially regulated by 
bFGF. Characterization of these proteins will be greatly aided by their purification 
from nuclear extracts. DNA affinity chromatography is one way in which specific 
DNA-binding proteins can be purified. Purified proteins which bind to the FRE, P42, 
or P149 can t)e separated based on their pis via isoelectric focusing. This would 
readily determine if the proteins binding to these sequences are different as our 
data suggests. Analysis of the sequence of these proteins could also determine if 
they are different from one another and more importantly determine if it is a known 
transcription factor or a novel group of transcription factors. 
Cloning of the cONA encoding the FRE binding proteins can enable studies 
to be done to determine if this protein regulates the mrfi/plf, stromelysin, mouse 
collagenase and tissue plasminogen activator genes, and any other gene promoter 
that contains a site similar to the FRE sequence. The site of the FRE-like sequence 
in both the mouse and human tissue plasminogen activator gene promoters lies 
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adjacent to the 12-0-tetradecanoylphorbol-13-acetate-responsive element (TRE) 
known to mediate activation by phorbol esters, while in the rat, the FRE lies 
adjacent to the cAMP-responsive element (CRE) shown to be required for cAMP 
responsiveness (59). Purification of the proteins binding the FRE could be used to 
determine if these proteins fonm heterodimers with other transcription factors such 
as the CRE-binding protein or AP1 proteins in the context of these promoters. 
Further elucidation of the mechanisms by which bFGF activates expression 
of the mrp3 gene promoter remains to be determined. Replacement of the FRE 
element in the -353/+65 region of the mrp3 promoter with the PI 49 or P42 
sequence would determine if the FRE is absolutely necessary the activation of mrpS 
by bFGF. 
While the FRE is a bFGF transcriptional activator element in the mrp3 
promoter, we provide evidence of another element that is bFGF-responsive. This 
element is probably located t)etween -81 and -46 as determined by the promoter 
deletion studies (see chapter two) and is a bFGF-repressive element. Further 
characterization of this repressive element could identify another unique FGF-
responsive element. As with many gene promoters, the regulation of the mrp3 gene 
promoter in response to various cytokines and growth factors is likely to be a 
delicate balance between activators and repressors effecting the basal 
transcriptional machinery. 
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APPENDIX 
Introduction 
There are three known promoters that have been identified for the 
mrp/ptf gene family, mrp3, plf149 and plf42, which are over 98% identical in 
sequence. We have identified a bFGF transcriptional element (the FRE for FGF 
responsive element) in the mrp3 promoter that actively binds proteins from 3T3 cells 
and placental and fetal nuclear extracts. The respective sequence in the plf149 
promoter, (P149) and the ptf42 promoter, (P42) which differ from the FRE sequence 
by two or three bp, respectively, has also t^een shown to bind nuclear proteins 
producing a similar shifted band as the FRE in gel shift assays. These three 
sequences, the FRE, P149 and P42, appear to bind a protein(s) with an apparent 
molecular weight of between 32 and 38 kOa as determined by UV cross-linking 
followed by SDS-PAGE analysis. However, only the FRE element linked in three 
tandem arrays upstream of a minimal thymidine kinase CAT reporter gene is 
responsive to bFGF in stably transfected 3T3 cells. This suggests that the protein 
that binds the FRE is a bFGF activated protein which is either the same protein that 
binds to the P149 and P42 in vitro, but in vivo binds with high affinity to the FRE and 
low affinity to P149 and P42, or alternatively, the proteins which bind the FRE with 
high affinity are different than the proteins which bind the P149 and P42. 
To determine if there is one protein that can bind to the FRE, P149 and P42 
with different affinities, or if there are different proteins that bind to these different 
sequences a series of competition studies were performed. In these competition 
studies, one of the sequences was used as the probe and all three were tested at 
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increasing concentrations for their ability to compete for the proteins bound to 
probe. These studies revealed that the protein binding to these different sequences 
competed off the best with the cognate oligonucleotide, while the other 
oligonucleotides competed off to a lesser extent. This data suggests that there are 
different high affinity binding proteins that bind to these different sequences. To 
provide futher evidence that the proteins binding with high affinity to each of these 
oligonucleotides is different, an attempt was made to purify the proteins using DNA-
affinity chromatography. Fractions containing the respective binding proteins were 
pooled, concentrated and used as samples on lEF (isoelectric focusing) and SDS-
PAGE gels. If the proteins binding with high affinity to the FRE, P149 or P42 are 
different but have the same molecular weight as our data suggests, then they would 
have different isoelectric points. The results of these studies indicated that the 
proteins were only partially purified as several bands appeared on the SDS-PAGE 
gels. UV cross-linking experiments to shift the DNA binding protein band on the 
SDS-PAGE gels did not produce a noticable shifted band. This suggests that either 
the binding proteins are a very small part of these partially purified samples or the 
UV crosslinking only resulted in a small proportion of the protein crosslinked to the 
DNA probe. Several different kinds of experiments were performed to try to identify 
differences in the DNA binding proteins based on their ability to bind to their 
respective DNA sequences including southwestems from SDS-PAGE and lEF gels, 
lEF-EMSA gels, and in gel DNA binding studies, but they were not successful with 
the amount of protein purified. 
Material and Methods 
Sequence-specific DNAstffinity cltromatography. Resins were prepared 
according to Kerrigan and Kadonaga (1) scaled for 5ml, using the specific 
oligonucleotides sequences for the FRE (5' GAT CCT ATA TCA GTG A AT CTA 
AAA 3') and (5' GAT CTT TTA GAT TCA CTG ATA TAG 3'); for P42 (5' GAT CCT 
ATA TCA GCA AAC CTA AAA 3') and (5* GAT CTT TTA GGT TTG CTG ATA TAG 
3'); and for P149 (5' GAT CCT ATA ACA GTG AAC CTA AAA 3') and (5' GAT CTT 
TTA GGT TCA CTG TTA TAG 3'). The single-stranded oligonucleotides were made 
and purified by the DNA Sequencing and Synthesis Facility (Iowa State University, 
Ames, lA). CNBr-activated Sepharose 4B was were purchased from Pharmacia 
Biotech, Pistcataway, NJ. Swiss 3T3 cell nuclear extracts were prepared as 
described (2) using 0.4 M KCI extraction solution. FREBP, P149BP, and P42BP 
activities were monitored by EMSAs previously described in paper 1 and chapter 3 
using the respective double stranded oligonucleotides as probes, made as 
described in chapter 3. The sequences used as probes for the FRE, P42 and P149 
are the same as described for making the DNA-affinity column, except the GATC at 
the 5' end is not present. The nuclear extract (3ml, approximately 10 mg/ml) was 
Incubated with approximately 175 pg of poly (dl-dC)-poly(dl-dC) (Sigma, St. Louis, 
MO) on ice for 10 minutes then centrifuged at 12,000 x g, 10 minutes, 4®C. The 
DNA-affinity chromatography was performed at 4®C. The supernatant, 0.75 mis, 
was loaded onto each column and washed with four 2 ml aliquots of Buffer Z' pH 
7.6 (25 mM HEPES, K+, 1 mM DTT, 20% (v/v) glycerol, 0.1% (v/v) NP-40) 
containing 0.8 M KCI. All the DNA-binding protein(s) from each column came out in 
the wash which was diluted to 0.1 M KCI in Buffer Z® and reapplied to the column. 
Then the column was washed with four 2 ml aliquots of Buffer Z* containing 0.1 M 
KCI. The DNA-binding protein(s) were eluted with step gradients of Buffer Z* 
containing 0.1 M increases of KCI. The fractions containing the DNA binding 
protein(s) (0.6 M to 1.0 M KCI) were pooled, concentrated and desalted to 0.05 M 
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KCI in Buffer Z® using Centricon-10 microconcentrators by Amicon (Beverly, MA). 
The samples were aliquoted, frozen in liquid nitrogen and stored at -ZCC. 
UV cmss-linking and SDS'PAGE. Samples from DNA-affinity 
chromatography were used in binding reactions as described in the EMSAs but 
without BSA and poly (dl-dC)-poly{dl-dC). The reactions were then UV irradiated for 
30 minutes with a 300 nm UV light source (Fotodyne, Inc., Hartland, Wl) at a 
distance of about 5 cm on ice. The reactions were resolved, along with protein 
molecular vveight standards, n a 12.5% SDS-polyacrylamide gel. The gel was 
stained with Coomassie blue, destained, silver stained (3), photographed, then 
dried and autoradiography was performed. 
lEF and SDS'PAGE southwestems. Partially purified FREBP, P149BP, 
and P42BP samples from DNA-affinity chromotography were run on lEF gels 
containing 3.9% acrylamide/0.0038% bisacrylamide, and 0.2 g/ml ampholines 
(8.5:1 of ampholines 3.5-1 Oiampholines 5-8 preblended) (Pharmacia Biotech) using 
the LKB Bromma Multiphore II Electrophoresis Unit and Thermostatic Circulator 
from LKB-Produkter AB (Bromma, Sweden). lEF gels to be transferred to 
nitrocellulose were made with Net-Fix for PAG from Crescent Chemical Co, Inc 
(Hauppaugem, NY). After running, the gel was transferred to Nitrobind 
nitrocellulose transfer membrane from Micron Separations Inc. (Westborough, MA) 
in 0.7% acetic acid for 1 hour at 15 V using the Trans-blot SD semi-dry tranfer cell 
from BioRad (Hercules, CA). The membrane was then washed with TNE-50 (10 mM 
Tris, pH 7.5, 50 mM NaCI, 1 mM EDTA, and ImM DTT), blocked with SW-BlockN-
50 (2.5% nonfat dried milk, 25 mM HEPES, pH 7.9, 1 mM DTT, 10% glycerol, 50mM 
NaCI, and 1 mM EDTA) for 2 hours at 37"'C, rocking gently. The SW-blockN-50 was 
removed and the membrane was rinsed in TNE-50 and incubated at RT in 10-20 
mis of TNE-50 and 10 mQ poly (dl-dC)-poly{dl-dC) for 5 min, shaking gently. FRE, 
P149, or P42 probes (2-5 million counts) were added and incubated at RT for 1 h 
with gentle shaking. The membranes were then washed 3 times with 20 mis of 
TNE-50, 10 minutes each, dried and exposed to a PhosphorScreen (Molecular 
Dynamics, Sunnyvale, CA) and analyzed on a Phosphoimager or exposed to Kodak 
X-Omat AR film at -70°C with an intensifying screen. Samples were also run on 
12.5% acrylamide, SDS-PAGE gels, and transferred to nitrocellulose in transfer 
buffer, pH 8.3 (25 mM Tris/CI, 192 mM glycine, and 20% methanol) using the Fisher 
Biotech Semi-Dry Blotting Unit Model FB-SDB-2020 from Fisher Scientific 
(Pittsburgh, PA). The membrane was washed, blocked and probed as described for 
the lEF gel transferred to nitrocellulose. Alternatively, the SDS-PAGE transferred 
blot was rehydrated in TKMED (10 mM Tris, pH 8.0, 50 mM KCI, 2 mM MgCl2, 
0.1 mM EDTA, ImM DTT and 20% glycerol), blocked in SW-Block (2.5% nonfat dry 
milk, 50 mM Tris, pH 8.0, 50 mM KCI, 0.1 mM EDTA, and 1 mM DTT) ST'C for 1 
hour, washed, probed and washed as described using TKMED buffer instead of 
TNE-50. 
In-gel southwestems. In-gel southwestems were performed on lEF and 
SDS-PAGE gels containing partially purified FREBP, P149BP, and P42BP samples 
from DNA-affinity chromotography. The SDS-PAGE gel was washed in two 100 ml, 
30 minute incubations of 2.5% TritonX-100, rinsed in TKMED, blocked in SW-block 
for 30 minutes at RT, rinsed in TKMED and incubated with FRE, PI 49, or P42 probe 
in 25 mis of TKMED shaking gently at RT for 30 minutes. The gels were then 
washed for 10 minutes in 25 mis of TKMED, wrapped in saran wrap and exposed to 
Kodak X-Omat AR film at -70®C with an intensifying screen. The lEF gel was rinsed 
in TKMED, blocked in SW-Block for 15 minutes, rinsed, probed, washed and 
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exposed to film as described for the SDS-PAGE gels. 
tEF-EMSAs. Partially purified FREBP, P149BP, and P42BP samples from 
DNA-affinity chromotography were run on lEF gels as described for the lEF 
southwestern. The lanes containing the sample binding proteins were cut into 
approximately 1 cm pieces and placed in the wells of the 4% high ionic strength 
PAGE gel used for the EMSAs. Twenty pi of the EMSA binding reaction 
components, as previously descrit)ed in paper 1 and chapter 3, containing either the 
PRE, P149, or P42 probe was added to the wells and incubated at RT for 45 
minutes before running the gel. The gels were then fixed in 10% acetic acid, dried 
and exposed to a PhosphorScreen (Molecular Dynamics, Sunnyvale, CA) and 
analyzed on a Phosphoimager or exposed to Kodak X-Omat AR film at -70°C with 
an intensifying screen. 
Results and Discussion 
Purification ofFREBPs, P149BPs and P42BPs. The DNA-binding proteins 
binding to the FRE (FREBP), P149 (P149BP), and P42 (P42BP) were partially 
purified with two different preparations of 3T3 cell nuclear extracts. The first 
preparation was loaded onto a Sephacryl S300 gel filtration column in the hopes of 
partially purifying the crude nuclear extract prep. EMSAs and Bradford protein 
assays performed on the fractions from the Sephacryl S300 column demonstrated 
its presence in the void volume fractions along with the majority of the other proteins 
in the crude nuclear extract indicating the gel filtration column did not work properiy. 
The fractions containing the DNA-binding proteins were pooled, incubated with p>oly 
(dl-dC)-poly(di-dC), centrifuged and the supematents were loaded onto the DNA-
affinity columns. This preparation on the columns was washed in Buffer Z* 
containing 0.1 M KCI and eluted off with step gradients of Buffer Z* containing 0.1 
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M increases of KCI. The DNA-binding proteins came off in the 2-1M KCI fractions 
which were then pooled, concentrated and desalted for use in other analysis. 
Interestingly, the DNA-afFinity resin containing the inactivated fc)eads also bound 
proteins which bind to the FRE. 
In the second preparation of DNA-binding proteins binding to the FRE, P149 
and P42 sequences, the gel filtration step was omitted and the DNA-affinity 
chromotography was performed as described in the materials and methods. 
Washing the columns loaded with the nuclear extracts with Buffer Z* containing 0.8 
M KCI caused the DNA-binding proteins to come off the column in this wash, as 
determined by EMSA analysis on the fractions and the wash. As a result, the wash 
containing the DNA-binding proteins was diluted to 0.1 M KCI with Buffer 2" 
containing no KCI and loaded on the respective columns, washed and eluted by 
step gradient, incubating each step of elution buffer on the columns for 5 minutes, 
as described in the materials and methods. The binding proteins were eluted 
between 0.6 and 1.0 M KCI. 
Analysis of the partially purified FRE, P149, and P42 DNA-binding 
proteins. The partially purified FREBP, P149BP, and P42BP samples from DNA-
affinity chromatography were run on a 12.5% SDS-PAGE gel, stained with 
Coomassie blue, destained and silver stained to detect protein bands. The first 
preparation of the DNA-binding proteins revealed two distinct bands running at 
approximately 33 and 36kDa in all the samples, including the sample eluted from 
the inactivated resin. A UV cross-linking experiment was p>erformed on these 
samples to determine if the protein bands could be shifted when cross-linked to the 
probe, identifying these bands as the DNA-binding proteins. The UV cross-linking 
experiment did not alter the intensity of the protein bands or shift them. However, 
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autoradiography of the gel confirmed the DNA-binding proteins were in these 
samples and the apparent molecular weight of the protein-DNA complex is between 
50 and 56 kDa. In these partially purified DNA-binding protein preparations, there 
might not have been enough of the specific DNA-binding proteins to visualize on 
SDS-PAGE gels by Coomassie blue and silver staining. The second preparation of 
the DNA-binding proteins contained more proteins than the first preparation. 
Several bands were found on the SDS-PAGE gel, Coomassie blue and silver 
stained. A UV cross-linking experiment was again performed to see if we could 
identify the specific DNA-binding protein band(s). There was again, no noticeable 
difference in the intensity and position of the protein bands produced, plus or minus 
UV cross-linking to the respective probes. This may be due to the fact that there 
was still not enough of the DNA-binding proteins in the sample to see. Alternatively, 
the UV cross-linking may not be very efficient i.e., it may not be cross-linking all of 
the probe to all of the protein, but only partially cross-linking them. 
Various techniques used to try and detect the FREBPs, P149BPs, and 
P42BPS and any differences between them based on their ability to bind to 
their respective DMA sequence. Southwestems of SDS-PAGE gels containing 
samples of the partially purified FREBPs, P149BPs and P42BPs were performed to 
determine if the DNA-binding protein containing bands could be identified. The 
proteins were transferred to nitrocellulose, then probed or, alternatively, the gel 
itself was probed (an in-gel assay) for proteins binding the the PRE, P149, or P42 
oligonucleotide probes as described in the materials and methods. The proteins 
transferred to nitrocellulose were blocked and probed using two different types of 
buffer, but neither produced any signal corresponding to a particular protein band 
when the PRE was used as a probe. Several possible explanations for these 
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results could be that there was not enough of the binding proteins to begin with, the 
DNA-binding proteins may not have transferred efficiently from the gel to the 
membrane, the DNA-binding proteins could be in an inactive binding conformation 
due to the SDS in the gel, ect. The in-gel southwestern did not produce a signal in 
the FREBP lanes but may have produced a signal in the P149BP and P42BP lanes 
which were probed in the presence of UV light. A repeat of this experiment would 
confirm these results. The absence of a signal in the FREBP lane may be 
explained by the smaller amount of FREBP in the sample compared to the P149BP 
and P42BP samples as judged by EMSAs. 
Southwestems were also performed on lEF gels containing samples of the 
partially purified FREBPs, P149BPs and P42BPs to determine if the DNA-binding 
protein containing bands could be identified and if so, that approximate isoelectric 
points could be determined. If the proteins binding the FRE, PI 49 and P42 double 
stranded oligonucleotides with high affinity were different, but have the same 
molecular weight, they may have different isoelectric points. The proteins were 
transferred to nitrocellulose, then probed or, alternatively, the gel itself was prot^ed 
(an in-gel assay) for proteins binding the the FRE, PI 49, or P42 oligonucleotide 
probes as described in the materials and methods. Neither the proteins transferred 
to nitrocellulose nor the in-gel proteins produced any signal corresponding to a 
particular protein band. The most likely explanation for these results could be that 
there was not enough of the binding proteins to begin with. It does not appear that 
the ampholines in the lEF gel will interfere with the signal of the DNA-binding 
proteins binding to their respective probes as the background of the in-gel assay 
was very low. 
lEF-EMSA gels were also tried to identify the DNA-binding proteins and 
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determine their approximate isoelectric points. The partially purified FREBPs, 
P149BPS and P42BPs were separated on an lEF gel. The lanes containing the 
samples were cut into pieces, incubated with the EMSA binding reaction mix, 
including the respective probe, in separate wells of the EMSA gel, then 
electrophoresed and analyzed as described in the materials and methods. 
Although there was no detectable shifted band in the first preparation of the DNA-
affinity binding proteins, the second preparation which contained more of the DNA-
binding proteins demonstrated a shifted band for P149BP at a pH between 4 and 6. 
These results suggest another method to pursue and develop which may provide a 
means to determine if the proteins binding with high affinity to the FRE, P149 and 
P42 double stranded oligonucleotides are the same or different. Again, as in the 
previous experiments, a purified sample with a higher concentration of the DNA-
affinity binding proteins is needed. 
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